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ABSTRACT
Effective use of data is believed to be the key to address systemic inefficiencies in
health innovation and delivery, and to significantly enhance value creation for patients
and all stakeholders. However, there is no definition for health data. Rather, data in
health is an assortment of observations and reports varying from science to clinical
notes and reimbursement claims that emerge from practice rather than design. What
is health data?
In this thesis we try to answer that question by looking at the system of health almost
exclusively as a system that generates, transforms, and interprets data. We overview
the different meanings data has throughout the health system, we analyze
systematically the inefficiencies and trends as they emerge from data, and propose a
new architecture for the system of health in which data is not present by accident. The
result of this thesis is a new architecture for the system of health that is consistent with
its present state but also consistent with a future learning system and a redefinition of
value in health care that is patient and information centric.
Thesis Supervisor: Luis Perez-Breva, PhD
Title: Research Scientist and Lecturer, School of Engineering
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CHAPTER 1: INTRODUCTION
The health industry has evolved from the scientific practice of medicine to a system
that spans across many disciplines, public and private initiatives, and vastly different
scales. This interconnectedness, in addition to the increase of the aging population and
the multiplication of disease categories, has led to a system that is continuously forced
to reconcile managing complexity with the opportunities presented by ad hoc and local
advancement. The Institute of Medicine estimates that the United States spends $2.6
trillion on health, with $750 billion wasted on procedural inefficiencies, unnecessary
services, and inflated costs; this amounts to a 30 percent loss, believed to be a
symptom of a suboptimal system that fails to meet the needs of its stakeholders
(Institute of Medicine, 2012).
Data in the health system is becoming more pervasive and its definition expands as
new devices and technologies are created. However, the system has yet to evolve into
an information system and data is managed within established stakeholder silos and is
generally inaccessible from the outside, with no standard grid for data to flow or
incentive to share it. This data is an assortment of observations and reports varying
from science to clinical notes and reimbursement claims that emerge from practice
rather than design. We believe this data holds more information than is currently used
and has potential to significantly improve the state of the health system.
The objective of this work is to arrive at a definition of health data and use that
definition to understand the system of health for its ability to generate, transform, and
interpret data. We view this as a prerequisite to understand the system of health as a
learning system. With that in mind, we overview the different meanings data has
throughout the health system, we analyze the inefficiencies and trends as they emerge
from data, and propose a new architecture for the system of health in which data can
no longer be thought of as accidental.
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The result of this thesis is a new architecture for the system of health that is consistent
with its present state but also consonant with the aspirations of a learning health
system. Our interpretation of learning, borrowing from the artificial intelligence
literature, is the process by which models and prior beliefs are updated given new data.
We try to reconcile this definition with the aspirations of learning in health.
We use the insight gained from analyzing the inefficiencies, in combination with the
principles of system design, to envision a health system that is patient and information
centric.
Through the methodical evaluation of data types, sources, and interfaces, we introduce
the conundrums in the current system. The two data problems outlined below
summarize the questions and impediments to learning that emerge from our overview
of the system through the lens of data.
Data problem #1: Data input to the clinical decisions that drive the entire system is
unnecessarily limited.
1.1 Data sourced outside the clinical environment, beyond the purview of the
provider system, does not have a defined use in the current health
system. This includes patient sourced data from physiological monitors
that do not yet have a standard entry into the care system.
1.2 Clinical decisions are made based on the data available. The selection of
data collected to make these decisions is largely driven by consensus
expectation and provider specific intuition. This suggests the
introduction of unintended bias and inconsistencies that easily propagate
to every decision.
1.3 There is no standard mechanism for the patient to provide feedback to
the product manufacturer or to the care system after an intervention.
Data problem #2: There is no mechanism for data to flow through the system. Rather
the flow of data is easily interrupted, which results in suboptimal
decisions and missed opportunities for knowledge sharing.
2.1 There is no standard way for specific patient information to transfer
between providers; either through referrals or during care transitions.
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The result is a patient history at the point of care that is guaranteed to be
incomplete.
2.2 Payors make decisions to reimburse for care based on transactional data
from the provider. The content of this data has limited clinical
information and is not a complete representation of the patient's health
status.
2.3 Medical product data generated during the development process is not
released in full after the product has been approved for
commercialization. The system relies on the summary data that is hard
to interpret in the context of a single patient, such as labels, medication
guides, and publications.
1.1 Background on the Health System
In this section we summarize the critical aspects of the health system that are needed
to understand the analysis done in this thesis, namely its six main stakeholders -
patients, providers, payors, manufacturers, regulators, and distributors - and the way
in which value is currently delivered. We use Crawley's system architecture
methodology to guide our definition of the system and to introduce the system
problem statement that can then be used to analyze alignment between stakeholders.
1.1.1 Stakeholder Definition
In principle, the patient is the direct beneficiary of the health system. The current
system considers individuals as patients upon their entry to the care system. The only
individuals today that are always considered patients are those with chronic conditions.
For our analysis of the future scenario we will eventually broaden this definition to
consider an individual who aspires to manage his health - either from within or outside
the care system.
Manufacturers of medical products, including drug therapies and devices, are solution
providers to the system. Manufacturers benefit from the revenue generated from the
sale of their products. The global pharmaceutical market is significant with revenue
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reaching $880 billion (Hirschler, 2012). The scope of the manufacturer stakeholder in
this thesis is primarily pharmaceutical companies, or drug sponsors.
Manufacturers and patients have remarkably different objectives. Manufactures
benefit from volume and repeated use of their products, while patients seek
personalized treatments and unique cures. These needs are indicative of the nature of
tensions in the system.
The other stakeholders are providers, payors, distributors, and regulators. Providers
are individuals or institutions that provide health care services and payors are the
funding arm for these services. There are nearly 200 major private payors in the United
States, the leaders including Aetna, Humana, Kaiser, Unitedhealth, and Wellpoint, with
collective revenues reported at $884 billion (HCAN, 2012). Payors coordinate directly
with distributors and providers to reimburse for the cost of products and services.
Distributors close the loop back to the patient by managing the medical product stream
from the manufacturers. The scope of the distributors used in this thesis is primarily
drug distribution from pharmaceutical companies to patients. This type of distributor
is also referred to as a pharmacy benefits manager, or PBM. The two largest PBMs,
CVS Caremark and Express Scripts/Medco, process the prescriptions of an estimated
200 million people in the United States, with annual revenues of each of these
companies exceeding $15 billion (NCPA, 2011).
Regulators assume the role of watchdog of the system to ensure product safety and
ultimately resolve the aforementioned tensions. Regulators coordinate closely with
the manufacturers and oversee the commercialization of products. The scope of the
regulator stakeholder used in this thesis is primarily the United States FDA's regulation
of drug products.
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Combined, these six stakeholders account for economic activity north of $2 trillion.
1.1.2 Stakeholder Network Flow
Figure 1 summarizes the nature of the flows between the stakeholders in five ways:
data, services, products, information, and money. We develop these flows from
interviews with stakeholders and review of the literature. The network flow is a
convenient way to synthesize the vastness of the system and we use the outcome to
identify the needs of each stakeholder (Appendix B). Following Crawley's framework,
we interpret these needs into goals to derive the system problem statement (section
1.1.3).
-- * Data
-- + Services
Legend 3- Products
-0 Information
-* Money
Figure 1: Stakeholder Network Flow
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A significant takeaway from Figure 1 is that individual health data, that is, observables
about a patient's health, are only exchanges at the patient-provider interface. All other
exchanges between stakeholders are on products, payment, services, and summary
information. The patient is the source of the data and is the receiver of care services,
however, information does not flow directly to the patient. Rather, it is managed by
the other stakeholders. As a matter of fact patients may find it cumbersome to gain
access to their own complete health record. This contradicts the concept of a patient-
centric system that has been previously defined by the Institute of Medicine (Institute
of Medicine, 2001). The network flow diagram shows that the patient supplies the
system with unlimited amounts of narrowly defined data and is not the primary
receiver of information.
1.1.3 System Problem Statement
According to Crawley's framework, the system problem statement takes the form of a
"to, by, using" sentence. Based on our stakeholder analysis, we derive the following
system problem statement for the current health system:
To treat symptoms and diseases,
By providing care services,
Using available medical information and products.
A recurring observation, pervasive in the literature, is the divergence of the current
health system with the intended system. The inefficiencies presented earlier in this
chapter indicate that the runaway costs and stagnant number of new drugs approved
are symptoms of this divergence. Our analysis of the current system aligns with this
shift, as we have indicated with the limited role of the patient. We believe that the
root of the problem may be found by examining how the system utilizes the
information it generates. Hence the objective of this thesis to focus on the data each
17
stakeholder needs and how they capture, use, and report the information as they fulfill
these needs.
1.2 Methodology
We collected information about data in the health system through stakeholder
interviews, from industry conferences and academic seminars, and through review of
the most recent literature. Our analysis of current stakeholders' perception of data
emerges from the reports published by key opinion leaders in health, namely the
United States Food and Drug Administration (FDA), European Medicines Agency,
United States President's Council of Advisors on Science and Technology (PCAST)
reports, and several reports by the Institute of Medicine. We complemented this
information with interviews to founders of companies working on implementing new
health innovations.
Throughout the thesis we use several system and visualization tools. We use Crawley's
framework of system design to define the stakeholder network, identify stakeholder
needs, and derive a system problem statement. We continue to use the stakeholder
method to organize the data, as a first level analysis. After compiling the data, we
apply adjacency and design structure matrices to assess the cross-stakeholder
communication and to define data dependencies. We use process modeling methods,
namely data flow diagramming, to represent the flow of data as the patient
interactions with the health system. We analyze our data flow diagram from various
perspectives, and we arrive at an architecture for a system design concept using
topology-preserving transformations of the flow diagram. We compare this method to
object-process modeling to verify the system characteristics, identifying form and
function. We compare our system representation with examples of data driven trends
to ground our process and provide relevant insight to the analysis.
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1.3 Thesis Outline
The thesis is organized as follows: In chapter 2, we describe the kinds of data that are
associated with each stakeholder, creating the landscape of data referenced
throughout the thesis. We explore the sources of data, how it is used, and where it
resides in the system. The data analysis continues in chapter 3 with visualizations of
data flow, defining the communication paths and dependencies. Taking a perspective
beyond the stakeholders, we further compare the data against a set of attributes and
assess value. In chapter 4 we merge the data analysis methods to derive the patient
interaction data flow diagram to holistically view and analyze data as a whole. We
discuss the impact when stakeholders have partial information through structured
review of the interaction diagram. We continue referencing the interaction diagram in
chapter 5, while we discuss the data driven trends and current state of the industry.
Chapter 6 we revisit the system structure and through an architectural transformation
derive the system vision for an improved health system that is based on knowledge
generation and learning.
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CHAPTER 2: HEALTH DATA LANDSCAPE
There is no single interpretation of data in the current health system. Figure 2 shows a
visualization of several kinds of data to allude to the complexity of the system and the
data it manages. In this chapter we define the meaning of health data. Results of this
research are a better understanding of what data means in the health system and more
insight into the role of each stakeholder.
r at*,*a-------
Figure 2: What is data?
This figure shows the landscape of kinds of data present in the health system. Colors reflect the
stakeholder managing the data and arrows correspond with dependencies.
Boxes indicate kinds of data of significant indexes used to sort data. This figure tries to capture
the complexity of sources and meanings of data in the system of health absent a structured
architecture for data in the system. The diagram is sorted by stakeholder; that sorting proves to
be insufficient to understand the value of data, the inefficiencies that emerge from the lack of a
data architecture, and the meaning one might want to ascribe to learning in health.
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2.1 Landscape overview
We follow the stakeholder convention defined in chapter 1. Namely, there are six
stakeholders - provider, patient, payor, manufacturer, regulator, and distributor. The
data landscape assessment starts with a structured review of the kinds of data that
each stakeholder manages. The data ranges from clinical measurements that inform
patient health to administrative transaction records that reimburse care services. The
breadth of kinds of data is as varied as the functions and needs of each stakeholder.
We review various types of documents and enumerate the data housed within,
resulting in nearly 500 distinct kinds of data. We sort the data into categories and
subcategories to ease our analysis.
Figure 3: Visualization of Health Data Categories
In Figure 3 we outline the data categories with the patient at the center because our
research suggests that no other element is shared across all the different kinds of data.
We revisit this point when we review the flow of information creation in chapter 4.
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Other data elements build off of the patient and are transformed, reformatted, and
modified as they flow through the system among the stakeholders. The figure shows
the extent of sources used to collect the data pieces and the organizational approach
taken to envisage an understandable, yet comprehensive landscape.
This chapter looks at the landscape of data, without considering the level of adoption
for each kind of data. The purpose is to give a holistic overview and we describe how
the data is being used in subsequent chapter. Perceiving data from its stakeholder
origin is convenient to start the assessment, but later we challenge the view and
suggest alternate categories of data.
2.2 Provider Data
Providers are in direct contact with patients, with whom they often have multiple
encounters a year. Providers collect, store, and maintain patients' detailed medical
and interaction records. The format of these records is changing from paper-based to
digital, with the worldwide adoption of electronic health records (EHRs). EHRs will
provide electronic storage of patient data and the content is indicative of the type of
data that is managed by the provider. Therefore, review of EHR data fields and format
sufficiently defines the provider data and is used as a starting point for this analysis.
We compared ten major EHR vendors including AthenaHealth, Practice Fusion, Care360
Quest, Epic System, eClinicalworks, and NexGen Healthcare. Although the products
themselves vary among vendors, the content of data within the EHR is comparable.
Figure 4 shows an EHR screenshot from NexGen Healthcare, displaying the various
fields of data.
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Figure 4: EHR screenshot from NexGen Healthcare
("EHR Market," 2009)
There are approximately 60 kinds of data that can be inputted into this single EHR
screen, collected during the patient interaction with the provider. Some are
administrative data such as name of patient, time, date; and some are clinical data such
as temperature, blood pressure, and allergies. Although the EHR has the data content
we seek for our analysis, the format is intended for provider input and it is not useful
for data analysis. We reorganize the data elements into the administrative and clinical
categories and visualize the hierarchical representation.
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*Provider
olnical Administrative
Figure 5: Visualization of Provider Data Categories
Created with Protege software to compile and categorize the data contents
within the 10 EHR implementations
The next two sections describe the kinds of data within these two categories in more
detail.
2.2.1 Administrative Data
Administrative data includes all of the information needed to identify a patient and
track encounters between the patient and provider. Administrative data is organized
into four categories: identifiable, encounter, billing, and follow-up; Figure 6 shows
further details. Patient identifiable data include name, demographics, contact
information, and status. Several more examples of data are enumerated in Figure 6.
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Administrative
PatientAdmininfo Billing
Insurance Codes
Contactinfo Diagnosis
Name Procedure
Address Services
Telephone Supplies
Uniqueldentifler PaymentAmount
Demograpics PaymentSource
0 HMO
Gender Medicaid
ZipCode Medicare
Race NoCharge
Ethnicity PPO
Status Privateinsurance
Marital SelfPay
Student WorkerCompensation
Employment
Occupation '
EmergencyContact EncounterRecord
Followuo AdmilssionRecord
Procrdon AppointmentRecordecord
Pharmacy DischargeRecord
Referral ReasonFor~lisit
Figure 6: Categorization of Provider Administrative Data
The encounter subcategory includes information about the patient interaction with the
provider such as appointment records, admission/discharge records, and reason for
visit. Referrals to other providers and corresponding contact information are included
in the follow-up subcategory, in addition to prescription refill requests and pharmacy
information. The billing subcategory contains the data used to generate a claim -
diagnosis and procedure codes - and information about a patient's health insurance
carrier and plan (section 2.4).
2.2.2 Clinical Data
Figure 7 shows the five main subcategories within clinical data: history, status, reports,
diagnosis, and treatment. Data in a patient's clinical history - diseases, family health,
past surgeries or operations, and administered vaccines - are inputs to provider
diagnosis. During a patient encounter, the provider characterizes patient status by
collecting subjective patient reported data like symptom descriptions, exercise and diet
routines as well as provider-measured data such as height and weight.
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Clinical
PatientStatus
Measurements
DeviceData
ElectricalMeasurements
BCG
ECG
EEG
Sp02
VitalMeasurements
BloodGlucose
BloodPressure
Diastolic
Systolic
BodyMassIndex
BodyTemperature
Crown-to-rumpLength
FluldBaIance
HeadClircumference
Hearing
HeartRate
Height
Movement
Perspiration
Pulse
PulseOximetry
RespiratoryRate
Vision
WalstToHIpRatIo
Weight
Sodal
DailyRoutine
DietPattems
ExercisePatterns
SleepPattems
Symptoms
Duration
Location
Onset
Severity
Type
Diamnosis
Disease
Condidon
Disorder
Overdose
Poisoning
TraumaEvent
imption Treatments
umption Procedures
Devices
Medication
Therapy
Figure 7: Categorization of Provider Clinical Data
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Revorts
Qualitative
AutopsyReport
ClinicalNotesReport
Appearance
BodyBuild
Deformities
Demeanor
Galt
Habitus
Hygiene
Mobility
Speech
VoiceQuality
PhysicalObservations
ConsultationReport
DischargeSummariesReport
EmergencyReport
HospitalizationReport
ImagingReport
CT
MRI
ObservationsReport
ProgressReport
RadiologyReport
SOAPReport
Quantitative
BiopsyReport
DiagnosticReport
DiagnosticTest
DlagnostlcTestinterpretation
DiagnosticTestResult
DiagnosticTestResultDate
LaboratoryReport
Blood
Histopathology
Immunology
Upid
Microbiology
Urine
OperativeReport
PathologyReport
PhyslcalExamReport
ProceduralReport
ProcedureDate
ProcedureResult
ProcedureType
SurgicalReport
Figure 8 represents graphically the patient status subcategory from Figure 7. This
illustration is useful for the patient input data discussion.
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Figure 8: Visual Illustration of Provider Clinical Subcategory, Patient Status
Clinical data that is collected in reports contains both quantitative and qualitative data
elements. Qualitative reports consist of consultation notes and progress reports.
These are typically subjective measurements or observations made by clinicians. These
reports, especially scanning reports require a degree of interpretation. Examples of
quantitative reports are physical exams, biopsy reports, and most laboratory reports.
This is actual measured and physical data that typically has a numerical value that is
documented during the patient encounter or on a test report.
Diagnosis data are statements of provider's interpretations of a patient's state based
on known, defined symptoms. This may be diseases, disorders, or conditions. There
are also several forms of diagnoses that include naming of a disease or dysfunction,
indication of degree of abnormality, or nosological coding. Each clinical diagnosis has a
corresponding diagnosis code, classified by the international classification of diseases
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(ICD). During the diagnosis process, physicians match their judgment on the state of
the patient to a standard diagnosis. Selected a diagnosis code is a form of matching to
a category system, with the ICD being the taxonomy of codes.
The ICD, updated and maintained by the World Health Organization (WHO), is used to
classify diseases and other health problems and the codes are the basis for
reimbursement. Figure 9 shows a screenshot from the ICD-10 online browser, which
includes over 16,000 codes.
Malignant neoplasms of respiratory and
intrathoracc organs
0 Malignant neoplasm of nasal cavity and middle
Mlignant neoplasm of accessory sinuses
Maigant neoplasm of lrn
Malignant neoplasm of trachea
Malignant neoplasm of bronchus and lung
Malignant neoplasm: Main bronchus
Malignant neoplasm: Upper lobe. bronchus
or lung
Malignant neoplasm: Midde lobe, bronchus
or lung
Malignant neoplasm: Lower lobe, bronchus
or lung
Malignant neoplasm: Overlapping lesion of
bronchus and hang
Malignant neoplasmn: Bronchus or king,
unspecified
Malignant neoplasm of thymus
P Malignant neoplasm of heart, medastinum and
pleura
i Malignant neoplasm of other and 1Il-defined
sites in the respiratory system and intrathoracic
organ
o Malignant neoplasms of bone and articular
cartilage
i Melanoma and other malignant neoplasms of skin
- Malignant neoplasm of bronchus and lung
C34.0 Main bronchus
Carina
Hilus (of lung)
C34.1 Upper lobe, bronchus or lung
C34.2 Middle lobe, bronchus or ung
C34.3 Lower lobe, bronchus or lung
C34.8 Overlapping lesion of bronchus and lung
[See note 5 at the beginning of this chapter]
C34.9 Bronchus or lung, unspecified
Malignant neoplasm of thymus
Malignant neoplasm of heart, mediastinum and pleura
xcI.: mesothelioma (C45-)
C38.0 Heart
Pericardlum
Exci.: great vessels (C49.31
C38.1 Anterior mediastinum
C38.2 Posterior medlastinum
C38.3 Medlastinum, part unspecified
C38.4 Pleura
C38.8 Overlapping lesion of heart, medlastinum and pleura
Figure 9: ICD-10 Screenshot of Lung Cancer Disease Classification
("ICD-10 Version:2010," 2010)
ICD-10 CM and ICD-10 PCS are the national modifications of ICD-10, which include
more detail about clinical modifications of diseases (CM) and procedures (PCS). These
databases are maintained by the United States' Centers for Disease Control and
Prevention (CDC) and contain 68,000 and 76,000 codes respectively ("ICD - ICD-10-CM -
International Classification of Diseases, Tenth Revision, Clinical Modification," 2012).
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The provider treatment subcategory contains information about the therapy or
medication that is prescribed as a result of a patient encounter or report analysis.
There are many other subcategories of medication, including drug type, dosage, and
frequency, as indicated in the medication history subset. The provider clinical record
includes the drug prescribing history, but does not account for when the drug is
actually distributed to the patient.
We make three observations based on the assessment of provider data. First, some of
the data collected is subjective and the provider needs to interpret the data based on
experience and knowledge. Second, the diagnosis is a result of a matching process to
taxonomy of codes, indicating that the provider must select a pre-defined category that
most represents the patient state. Third, the provider data collection is more focused
on diagnosis and intervention selecting, rather than monitoring for outcomes.
The EHR and ICD standards suggest commonality, however there is still much
operational and workflow variance among providers, resulting in a wide range of data
quality. As well, patients visit several different providers during their lifetime, so the
records kept by a single provider do not always reflect the patient's complete medical
history. Next, we discuss data that is collected and owned by the patient that can be
used to supplement the data managed by the provider.
2.3 Patient Data
From a data perspective, patients are the ultimate source, with data being collected
through testing, sensing, monitoring and direct query. However, the way in which the
health system incorporates this data varies by stakeholder.
New technology is enabling the collection of data outside of the traditional provider
environment. The kinds of data discussed in this section are patient input data into
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personal health records, dynamic physiological signals, and patient acquired genetic
information.
2.3.1 Personal Health Record
Much of the data captured in a patient's medical record or EHR originates from the
patient. During patient encounters with providers, patients share information about
their symptoms and behaviors, and report on treatment feedback. In most cases, this
is where data input stops. Patients typically do not document this kind of data, so the
provider record is relied on for data collection and storage.
In some cases, patients may decide to maintain a health diary or personal health record
(PHR), although currently not the norm as PHR adoption is low. PHRs are effectively
like EHRs but are managed by the patient. A patient may use a PHR to collect all health
information and maintaining a personal medical record for individual access. In
addition to information from their EHR like allergies, lab results, and medications PHRs
may include patient-reported outcome data and passively collected data from
monitoring devices. Examples of PHR vendors for the patient consumer include
Doclopedia, EmryStick, JuniperHealth, MiVIA, and ZweenaHealth.
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Figure 10: ZweenaHealth PHR Features
("ZweenaHealth," 2012)
Services like Zweena claim to enable 24/7 access to complete medical records through
an online secure platform. A benefit to the patient may be convenient management of
the compilation of their health data from various sources. Patients own their PHR and
have the option to permit external access or integration to a provider EHR system. The
data in the PHR is from the perspective of the patient, while the EHR remains provider-
focused. Both datasets may be used in tandem to yield a more holistic view of the
patient's medical status, given the increase adoption of PHRs.
2.3.2 Physiological Measurements
Often the physiological signals measured during a patient-provider encounter, like
blood pressure or heart rate, are not reflections of day-to-day average measurements.
As well, these point-of-care collected data points do not give indication to conditions
like arrhythmia, seizures, or other episodic driven disorders. Remote physiological
measurements create a new category of data, which is in between encounter
measurements, and may give a different view on of data. The results can provide
additional data to enhance the clinical assessment of the patient. Table 1 lists several
of the physiological signals that can be dynamically measured.
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temperature of mouth, skin, ear, under arm, or
anus
Aoral normothermia 37C) ___
arterial palpation of the heartbeat to determine
cardiac performance
number of heart beats per unit time (typ 60-90
bpm), measure of exercise efficiency
pressure exerted by circulating blood upon the
ure walls of blood vessels (avg 110/65 - 140/90
mmHg), measure of cardiovascular health
number of breaths per unit time (60 sec) typicall
ate 12-20 for adults, indicator of potential respirator
dysfunction
ce human homeostasis, amount of fluid lost from tibody is equal to the amount of fluid taken in
thermoregulation, production of a fluid consistin
n primarily of water as well as various dissolvedsolids (chiefly chlorides), that is excreted by the
sweat glands
t
Vision
hearing
weight
--
height
body mass
index
waistto hiprat
blood glucos
EEG
ECG, EKG
BCG
SpO 2
blood press
respiratory r
fluid balan
perspiratio
movemen
io girth ratio - measure of regional fat distribution-
e measurable amount of glucose (sugar) in the
blood
Electroencephalography, electrical activity in br,
to assess brain death, seizures
Electrocardiography, electrical activity in heart t
assess regularity of heart beats
ballistocardiograph, measure of ballistic forces c
the heart
oxygenation, oxygen saturation of tissue, blood
body
temperature
pulse 
heart rateI
Table 1: Description of Physiological Measurements
("Epson Enters Healthcare Business with Wristwatch-Type Pulse Monitor," 2012)
("Wearable Blood Pressure Sensor Offers 24/7 Continuous Monitoring," 2009)'
("Measuring and Managing Fluid Balance," 2011)
Automatic collection of physiological measurements is possible with the use of devices
and monitors. There are several hundred ambulatory devices that attach to the body
to enable dynamic monitoring of vital signals. Some of these devices are offered direct
to consumer (patient), others are provider prescribed. The collected data can either be
stored on the device, smartphone, or synced to a PHR/EHR platform. Many of these
systems, approved as medical devices, alert the patient and/or provider of
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-I -----
thermometer, thermocouple,
thermistor
finger touch, LED/photodiode,
photoplethysmography sensor,
electrode monitor on chest or wrist
sphygmomanometer, pulse wave
velocity
y counting breaths, transducing
sensor
e observation, body weight, urine
g output,blood chemistry
thermal sensor, LED/pH sensor
accelerometer, pedometer, motion
sensor
nal Snellen chart
audiometer
i mass scale
linear scale
n calculated from weight and height
measurements
calibrated tape
enzyme electrode, glucose
oxidase strip
ain scalp electrodes
chest electrodes, sensor
accelerometer, electrodes
near infrared spectroscopy, pulse
oximeter
physical activity
visual acuity, acuteness or clearness of vision,
which is dependent on the sharpness of the retii
focus within the eye and the sensitivity of the
interpretative faculty of the brain
perceive sound by detecting vibrations through
organ such as the ear
lbs / kgs, needed for medicine dosing
inches / meters, needed for medicine dosing
BMI, or Quetelet index, heuristic proxy for huma
body fat based on an individual's weight and
height, indication of obesity
abnormalities and recommend interventions. Table 2 highlights the various features of
selected devices with a range of usages.
a corventis- V V V 6/ I V
SoteraVVV V
&DYMCDM I A
+fitbit
Withings V v v v
VitaDock--- - - V V V
digifi v V v v
Table 2: Patient Monitoring Devices
These monitoring devices improve signal capture from an individual data point to a
data series collected over a period of time. Data trends can then be analyzed to
develop a more complete assessment of patients' health. For instance, Corventis'
AVIVO* system features a wearable device that attaches to the chest and measures
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fluid status, heart rate, respiratory rate, posture, activity, and ECG. This data is
transmitted to a handheld device that is connected to Corventis' clinical monitoring
center. The physiological trends are reviewed by the patient's physician who uses the
data to track heart failure and guide clinical decisions, enabling early
intervention. (Corventis, 2012)
How the AVIVO' MPM System Works
Remote monitoring of physiological parameters
aink Mobdie
..... WerableNX i n TransmittetWearable Pix,
automatically collecting
and transmitting data
Physcin Access Data Analysis
Figure 11: Corventis' Mobile Patient Management System for Heart Failure Patients
2.3.3 Genetic Data
Over 1,300 genetic tests have been developed since 1986 with about 1,000 currently
available from testing laboratories ("Personalized Medicine: Trends and Prospects for
the New Science of Genetic Testing and Molecular Diagnostics," 2012). Genetic data is
determined by collecting a sample of DNA from blood or saliva that may be used to:
* diagnose disease
* confirm or rule out suspected genetic conditions
* determine risk of developing or passing on a genetic disorder
* inform the type or dose of a drug that will yield an effective response
* determine variety of predispositions, characteristics, and phenotypes
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Testing service companies now offer DNA analysis direct to consumer. For
approximately $100, individuals can obtain genetic comparison of their DNA to 120
diseases, 57 traits, 48 carriers, and 21 drug responses ("Genetic Testing for Health,
Disease & Ancestry; DNA Test - 23andMe," 2012). This is a limited amount, compared
to the 16,000 ICD disease codes. Direct to consumer genetic testing vendors include
23andMe, deCODE Genetics, easyDNA, and VuGene. It is intended and claimed by
these vendors that genetic data may be used to individualize care and inform clinical
decisions.
Advancements in science, technology, and information systems are enabling patients
to take a more active role in their health and be at the forefront of their own data
collection. Monitoring devices are infiltrating every day life and knowledge of the
chemical makeup of the human body continues to advance, and so do the personal
data collection opportunities. Services are beginning to cater to the well-informed
patient, although adoption by patients remains low.
2.4 Payor Data
Most payors, public and private, use the data formats guided by the ICD standard,
which enables comparison and we can analyze them together. Each interaction
between the patient and provider is translated into a coded claim used for billing and
reimbursement. Interactions include outpatient visits, inpatient stays, laboratory
services, prescription filling, and medical device distribution. The claim includes the
date and place of service and applicable codes, which are used to calculate the
payment amount. The Centers for Medicare and Medicaid Services (CMS) provide
numerous forms to assist payors in collecting the data required for provider
reimbursement. Private health insurers, like Aetna and Tufts Health Plan, may use
different claim forms than CMS-1500, but the content is nearly identical. A sample
claim form is shown in Figure 12.
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HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE 08/M6
BLUE CROSS AND BLUE SHIELD OF MN
914 43RD STREET
SUITE W-201
ST PAUL, MN 00123-0098
t
-
PICA PICA
1. MEDICAE MEDICM) CHAMPVA GROUP FECA OTHER I a. INSURED'S I.D NUMBER (Fcr Program in Item 1)
l,01oafia] A4dr*0 (sponoouss 5 17 ([]iMaetarm10e)y (sN 0ork p[] s) [1011 X987-1234A-032
2. PATIENTS NAME (Lat Nam. FAt Nane. Middle InWW5 3. PATENT'S RTH DATE SEX A INSURED'S NAME (Lam Nme, First Name, Midle InItal)
THOMPSON, ANNE MARIE, H 12 12 1958 M] F THOMPSON, ROBERT, H
& PATIENT'S ADDRESS (No.. 1ree 6. PATIENT RELATlONSHIP TO INSURED 7. INSURED'S ADDRESS (No., Sro.e
5813 CRADLE ROCK COURT seIL] spre. [CNd 1Er 5813 CRADLE ROCK COURT
CITY STATE 8. PATIENT STA1US CITY STATE Z
ST PAUL MN single [ Mward [x Oth* 7 ST PAUL MN
ZIP CODE TELEPHONE Qnclude Alea Code) ZIP CODE TELEPHONE (Include Area Ccdo)
Full-Tim Part-Tim
00123-0054 (001) 5551212 Empd tudn ,= stud.J El 00123-0054 (510 ) 5551212 0
9. OTHER INSURED'S NAME (Last Noa. First Nam. Middle WInal) 10. IS PArI ENT'S CONDITION RELATED TO' 11. INSURED'S POLICY GROUP CR FECA NUMBER
THOMPSON SR, ROBERT, G BSBS54321
a, OTHER INSURED'S POUCY OR GROUP NUMBER a. EMPLOYMENT? (Curnt or Previou* a. INSURFDS DATE OF BIRTH SEX
X0987654321 YES XjNO 01 _18_ I1956 MF
bOTHER INSURED'S DATE OF BIRTH SEX b. AUTO ACCIDENT? b. EMPLOYER'S NAME OR SCHOOL NAMEMM DOGEPAC)Mt
12 12 1918 MX F YES NO IMN I PRICE WATERHOUSE COOPERS
c EMPLOYER'S NAME OR SCHOOL NAME c. OTHER ACCIDENT? c. INSURANCE PLAN NAME OR PROGRAM NAME z
US ARMY (RETIRED) YES [ NO BLUE CROSS BLUE SHIELD PPO 5-
d. INSURANCE PLAN NAME OR PROGRAM NAME I0d RESERVED FOR LOCAL USE d. 18 THERE ANOTHER HEALTH BENEFIT PLAN7
MAMSI SENIOR PREFERRED PPO CLAIM ATTACHMENT [x1 YES ["NO #yv, return toandcompleteItem9a-
READ BACK OF FORM BEFORE COMPLETING A SIGNING THIUS FORM. 13. INSUREDS OR AUTHORIZED PERSON'S SIGNATURE I authorize
12, PATIENS OR AUTHORIZED PERSON'S IGNATURE. I autoriohe rdease ofanymedicSqm or ottr itiron necessary payment of medical beei.ts to the rIrnooar ad ohys=can or sipplm tot
to porn... this claim. IAlso request payment O government benfrt ahoer to myself or to !he party ro accepts assignrent sarvices described bealow.
SIGNED SOF DATE 07/01/200 SIGNED SOP
1
2
3
4
5
6
14. DATE OFCURRENT: ILLMS9 fis asyptom 15. PATIENT HASHAD E s1S6. IS DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION
GIVE FAIRSTr DAEMMIDOIA 2fl74 PREA7 101 2007 FROM07 101 12007 To 07 20 2007
17. NAME OF REFERlNG PROVIDER OR OTHER SOURCE 17.1 - r- - -18. HOSPITALZATION DATES RELATED TO CURRENT SERVICES
ROBERT SMITH MD 7b NR 0005678 FROM- --20-7 TO 07 1 . D oy
19. RESERVED FOR LOCAL USE 20. OUTSIDE LAB? $CHARGES
1234567890A [j]YES [ NO 150050 I
21. DIAGNOSIS OR NATURE OF LLNESS OR INJURY (Areo trms 1. 2.3 or 4 to lam 24E lby Lin 22 MEDICAD RESUBMISSICNCODE ORIISNALREF, NO
1.1E88 5 0 190 1 1234S6799S I ABC1234567990
23 PRIOR AUTHORIZATION NUMBER
2 E2i 903_ 5490 123456789123456789123456789555
24. A. DATE(S) OF SERVICE C. I D.PROCEDURES.SERVICES. ORUPPLES E. JF H I . 2From To IR E G (Explain Unueuel Circumace DI3NOSIS B tD. RENDERING 2
MM DD YY MM DO W LREEMG CPDMCPCS MODIFER POINTER ISCHARGES S A PRODEER 1D.
7ZIN 1245 MW 1426 TINE 90 HEUs --123450789D2
07 101 107 07 !05 !07 122 1 N 00770 25 26 LT RT 134 1 8751001 61Y NPI 012345789
711|"IN 2245 EMD 1415 A AD123 67890-
07 01 07 10701 07 122 1 Y 00770 P2 1P2 P2 12I 134 1 875100 90 N NPl 0123456789
WzXRY WALKER NL!-I 13 4 -7 pz~ --
07 | 01 107 07 |01! 07 112 IN IE1399 1 25126 26 1281 12 1 165150 1 N NPI 0123456789
N400026064071 { GOBULIN Ih"N*iVta lUo V41? AV 13 1235679901
07 01 | 07 107 01 07 111 N J1563 RT1 LT 128 1291 13 5001 00 20 N NP 0123456789
m222BIes 7 NUs 1 234S6789901
07 01 07 107 02 07 1 11 1 N A6410 I 13 15 1001 2 I NPI 0123456789 vi
020,20011346780 N 1 12345679901 !
500100 21N 1~ 012345678907 ' 01 's I o7 ! o7 o7 1 i  Y A41o 25C1 26 1RT TX 1 1% 500 00|2|NN1 02468
25. FEDERAL TAX .D. NUMBER SSN EIN 26. PATENT'S ACCOUNT NO 27 ACCEPT ASSIGNMENT? 2. TOTAL CHARGE 29. AMOUNT PAID 30. BALANCE DUE
555666777888 D Fx 20070613235249 E 2930150 5 3of49* 2900!01
3. SIGNATUREOF PHYSICIANOR EUPPIER 32. SERVICE FACILUTY LOCATION I FORMATION 3. BIWN PROVIDER INFO & FH a (012) 5551212
INCLUDINIG DEGREES OR CREDENTIALSIomfy that theestrirmetfenfte rews LABOORP DIAGNOSTC THE PEDIATRICS GROUP
appl lo thisllandaa nd a pan l*) 123 HEALTHCARE LANE 1234 MAIN STREET
SOF 12/12/2008 ST PAUL MN 00342-1111 COLUMBIA MN 00123-0765
SIGNED DATE * 0123454789 l 13123456789 a 012341!6789 b-13987654321
P"LEASE PRINT OR TE APPROVED OMB-098- g FM )MS-1 5U0 (UOIU5)
Figure 12: CMS-1500 SmartForm, Health Insurance Claim Form
("New CMS-1500 (08/05) Healthcare Claim PDF SmartForm With Built in 837P EDI Capabilities," 2007)
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As described in the provider section, clinical information about a patient is translated
into a standard code that represents the patient diagnoses, procedures performed,
services delivered, or supplies tendered. Example codes are shown in items 21, 24D,
and 24E in Figure 12 and their meaning can be searched on various online databases,
including the WHO and CMS. Most every disease and clinical service has a
corresponding code, used nationally for billing. This format defines the communication
structure between providers and payors.
Dates are recorded on a claim to capture the time sequence of clinical events. The
codes captured in a claim represent the closest description of a diagnosis, procedure,
or service for which a code exists. Due to the code renewal schedule, new procedures
may be available that do not yet have a unique code. As well, due to the coding
complexity and variations among providers, errors in claims are frequently observed.
The recorded claim error rates for various payors have ranged from nine to sixty
percent, according to the American Medical Association's (AMA) annual health insurer
report card (American Medical Association, 2012).
Besides for the series of codes, the payors collect additional information about the
patient and provider. Some of this information is also included on the claim form,
while some is collected during enrollment. The five categories of data payors use to
process reimbursements and management patients are patient administration,
product, medical claim, pharmacy claim, and provider information, as shown in Figure
13. These five categories represent five separate databases that payors manage.
37
MedicalClaim
Record0finteractions
Outpatient
Inpatient
Emergency
Dates
Dental
DateOfService
DateOfFirstSymptom
DateFlirstConsulted
DateOfAccident
DateOfPregnancy
DateOfPridrillness
DateOfDisability
DateReturnToWork
DateOfAdmission
DateOfHospitalization
DateOfDischarge
DateOfPayments
Codes
Diagnosis
Primary (ICD)
Secondary (ICD)
Procedures
HCPCS
CPT
CDT (dental)
CodeModifier
ICD
Revenue
Services
Laboratory
Supplies
MedicalDevices
Drug
Resubmission
Costs
ChargeAmount
PaidAmount
PrepaldAmount
CoPay
Coinsurance
Deductible
Reimbursement
Days/Units
Denialinfo
PriorAuthorationNumber
Figure 13: Categorization of Payor Data
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PharmacyClaim
Druginfo
DrugCode (NDC)
DrugName
PrescriptionInfo
Number
Date
New/Refill
DosePerDay
DaysSupply
Quantity
Strength
Generic
FormularyCode
RouteOfAdministration
Natureofillness
NatureOnfnjury
PharmacyInfo
PharmacyName
Pharmacyidentification
PharmacyAddress
PrescribingPhysicianinfo
PurchaseDate
Costs
ChargeAmount
CoPay
Reimbursement
Providerinfo
ServiceProvider
Name
Gender
DOB
Contactinfo
ProviderDemographics
Providerldentification
Uicenseinfo
ProviderTaxID
ProviderType
Specialty
PrimaryCarePhysician
PrescribingPhysician
PlaceOfService
FacilityType
FederalTaxD
Address
Telephone
Referralinfo
EMRVendor
AcceptingNewPatients
The data in the patient administrative and product categories may be used before a
patient receives care to vet plan eligibility and determine coverage type. Once care has
been received, claim processors assess patient eligibility and payment applicableness of
the services rendered. Most health care insurance plans have coverage for
prescriptions and the details of drug distribution are recorded on a pharmacy claim.
This includes the drug code, strength, dosage, and quantity as well as pharmacy and
prescribing physician information. Pharmacy claims themselves do not include the
diagnosis code relevant to the prescription, but may have a brief description of the
patient's condition. Currently, there is no standard link between pharmacy claims and
medical claims. Pharmacy related data is further discussed in section 2.7.
The last category is the provider, which includes data about the physician submitting
the claim. The payor requests standard information (national identification number,
license, specialty, and facility type) in order to properly identify the provider and verify
credentials.
The volume and availability of claims have led to analytic efforts aimed at optimizing
health care. Groups of payors combine claims about their patients/employers into
commercial claims databases, such as PharMetrics, MarketScan, and Medco. Recently,
several states in the United States have initiated the development of an all-payer
claims database (APCD). This database combines claims of all members within as state
for the purpose of facilitating a holistic view of cost and utilization (Patrick, Murray,
Bigby, & Boros, 2012). These efforts to collate different kinds of data for the purposes
of analysis and research stress further the need to ensure better quality assurance
practices.
The transactions between the payor and provider rely on a series of codes, yet result in
decisions that drive the health care system. With limited clinical details to support the
claims, the payor's assessment of the value of patient care is based on claim
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interpretation. As well, the payor manages five separate databases for each function it
provides and experiences an abundance of information due to the nature of the data.
The availability of data presents opportunities to relate and compare, regardless of the
quality of the data.
2.5 Manufacturer Data
This section overviews the variety of data that is managed by the manufacturers of
drug products. We describe the data that is collected during each development phase:
pre-discovery, discovery, development, and clinical trials.
The time from drug discovery to adoption is approximately ten years and over that
period manufacturers store and maintain data for compounds. The data originates
from basic science, pre-discovery, discovery, and evolves into information about the
safety, efficacy, and effectiveness of a compound in humans. Several kinds of data are
introduced into this process and Figure 14 gives an overview from the perspective of
data. We use the United States FDA's regulatory process as an example for this
section.
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Figure 14: Categories of Data in the Drug Development and Approval Process
In order to license a drug, regulators must review the clinical trials and other
documentation that supports the benefit claims of the drug made by the sponsor, or
drug manufacturer. Manufacturers have incentive to adapt their processes and how
they manage data to the rules and communications around the regulator.
The manufacturer and regulator sections that follow individually describe the data
elements that are enumerated in Figure 14.
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2.5.1 Drug Discovery
Scientific analysis of molecular targets and identification of molecules that interfere
with such targets occurs during the drug discovery phase. After the target is
determined, 3 to 7 more years are required to determine the lead compound. The
result of the phase is the emergence of a candidate drug that can then be tested in the
lab in vitro and in vivo, during the preclinical testing phase. The goal of this phase is to
establish the safety and efficacy parameters before the compound enters humans. The
lab and test data compiled from this phase is issued to the FDA as an investigational
new drug (IND) submission. Figure 15 summarizes the data contained in an IND.
- physical & chemical - pharmacology/
characteristics toxicology summary
- stability -interspecies comparisons
- name & address of toxicity studies
manufacturers - reproduction studies
- process/substance mutagenicity studies.
controls Absorption, Distribution,
- solid-state drug Metabolism, Excretion
substance form (ADME)
- packaged samplis
Figure 15: Data Included in IND
(Investigational New Drug)
2.5.2 Drug Development
Once the regulator approves and reviews the IND, drug sponsors can then begin testing
their product in humans. The clinical trial protocol is a formulary of the data that needs
to be collected during a study to answer specific research questions. The test
hypothesis is evaluated through measuring endpoints that are defined in the protocol.
These endpoints are typically measurements of response rate or survival time. The
protocol describes the type of people that may participate in the trial, schedule of
tests, procedures, medications, dosages, and study length. Participants in a clinical trial
are monitored regularly to assess health, disease state, and determine the safety and
efficacy of the treatment.
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The data is collected as per the protocol and reported on the case report form (CRF),
which is the data-reporting document that is used during the trial. The CRF is designed
to organize the data collection and allow for efficient analysis by biometricians and
statisticians. CRFs are used to track subjects during clinical trials and the data
contained is used to make decisions about the drug, benefits, risks, and marketability.
CRFs can either be in paper-based or digital formats. Electronic CRFs (eCRF) are
referred to as remote site monitoring (RSM) or remote data entry (RDE). Procedurally,
there is no difference between the CRF and the EHR, except the protocol provides a
means of what to collect (prescriptive) and the CRF is designed for analysis and
monitoring. Figure 17 shows an excerpt from a CRF and Figure 18 summarizes the
nature of the CRF data.
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Figure 18: Categorization of Case Report Form (CRF) Data
There are three major parts of the CRF: header, safety, and
efficacy. The header includes the study number, site/center
number, subject identification number, and subject demographic
information. The safety section includes data describing medical
history, physical exam results, vital signs, patient disposition,
concomitant medications, and adverse events. Adverse events
include any untoward medical occurrence that results in death, is
life threatening, requires hospitalization, or causes a significant
incapacity. The final section of the CRF is efficacy, which includes
information on baseline and endpoint measurements.
Once a study is complete, the CRF is collated into a clinical study report (CSR) and
submitted to the FDA (Figure 19).
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Figure 19: Data Included in Clinical Study Report
2.5.3 Clinical Trials
Clinical trials are divided into consecutive phases, with an increasing number of
patients. The chart below describes the differences between each phase and the type
of data that is collected at each stage.
Number of Primary Secondary Study
people purpose purpose design
- tolerability
20-80 * safety - drug reaction
Phase I healthy - dosing (ADME)
subjects - side effects * pharmacokinetics
e pharmacodynamics
100-500 efficacy
patients with - sey - safe dose range randomized,
Phase II targeted effetveness - active dose range double-blinded
condition,*efetvns
disease
1,000-5,000 - safety profile
Phase Ill patients - expanded randomized
(diverse) testing of blinded
effectiveness
additional safety test drug for additional
Phase Illb data conditions for which it
may prove useful
expand testing of compare long term
proven drug to effectiveness and/or
Phase IV broader patient cost of drug to other
population marketed drugs
Post new age group, focus on unknown
Approval new patient side effects or risk
Studies types factors
Table 3: Clinical Trial Phases
(FDA Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs
and Biological Products, 2012)
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There are many sources of information for clinical trials. The NIH manages the web
database, ClinicalTrials.gov, which provides information about nearly 140,000 studies,
both in the recruiting phase as well as completed trials. The kinds of information that
are reported and listed with each trial summary on ClinicalTrials.gov are (NIH, 2007):
* disease or condition and experimental treatments studied
* title, description, and design of study
* requirements for participation
* locations where the study is available
* contact information
* links to relevant information at other health web sites, such MedlinePlus and
PubMed
Some of the completed trials have reported results such as (NIH, 2007):
* participant flow
* baseline characteristics
* outcome measures and statistical analyses
* adverse events information
* administrative information
The same kinds of trial information are also shared by private sponsors through clinical
registries.
The manufacturer makes decisions about whether to pursue a drug through review of
the data created in the drug discovery and development phases. The data is collected
into various standard forms including INDs, CRFs, CSRs, and populated in clinical trial
databases. We believe the CRF contains the raw patient data that is most similar to the
EHR. Manufacturers share INDs and CSRs with the regulator, but do not share the
CRFs, which contain the most pertinent, patient level data.
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2.6 Regulator Data
Regulators work closely with manufacturers during the approval process and provide
standards for data transfer. The regulator is not permitted to share data, even if two
manufacturers are developing a similar drug, due to confidentiality policies. The next
sections describe the contents of the new drug application (NDA) submission, drug
label, and other data that is collected and maintained by the FDA.
2.6.1 New Drug Application (NDA)
The NDA is a submission format to the FDA for drugs that have passed clinical trials.
The NDA must be approved by the regulatory bodies prior to commercialization, for the
sale and marketing of new drugs.
The goals of the NDA are to provide enough information to permit a FDA reviewer to
reach the following key decisions (FDA, 2012a):
e Whether the drug is safe and effective in its proposed use(s), and whether the
benefits of the drug outweigh the risks.
e Whether the drug's proposed labeling (package insert) is appropriate, and what
it should contain.
e Whether the methods used in manufacturing the drug and the controls used to
maintain the drug's quality are adequate to preserve the drug's identity,
strength, quality, and purity.
The documentation required in a NDA should tell the drug's whole story: what
happened during the clinical tests, what the ingredients of the drug are, the results of
the animal studies, how the drug behaves in the body, and how it is manufactured,
processed and packaged (FDA, 2012a). In order to answer these questions and provide
a comprehensive documentation package, the FDA requires that the NDA be organized
into the following six technical sections:
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Figure 20: Six Sections of the New Drug Application (NDA)
Adapted from (FDA, 2012a)
Sections (i) chemistry and manufacturing and (ii) nonclinical pharmacology and
toxicology are submitted to the FDA in the IND and are updated throughout the
human trials. Section (iv) microbiology is informed by the data collected in the
discovery phase and analysis of lab data from the clinic. The other three sections,
(iii) human pharmacokinetics, (v) clinical data, and (vi) statistical analysis rely on
input from the clinical trials and data reported on the CSR. The clinical data
section must also contain the case reports for all patients who died during a study
and for patients who did not complete a study because of any adverse event.
Case report tabulations must be submitted for individual patients for the initial
clinical pharmacology studies, controlled clinical studies, as well as all
corresponding safety data.
Other information that is contained in the NDA submission is:
- Pharmacological class
- Scientific rationale
- Intended use & potential clinical benefits
- Benefit/Risk analysis
- Patent information
- Postmarketing studies
- REMS
- Foreign marketing history
Figure 21: Additional Data Included in a New Drug Application (NDA)
(FDA, 2003)
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REMS are the FDA's risk evaluation and mitigation strategies that are enforced onto
manufacturers to ensure that the benefits of a drug outweigh its risks (FDA, 2012b).
Depending on the safety profile of the drug, REMS may be required for approval or if
new safety information is learned about the product. REMS take various forms and are
agreed upon between the manufacturer and FDA. The basic components of REMS
include (FDA, 2012c):
e medication guide - pamphlet distributed with drug
* communication plan - informing key audiences about risks
e elements to assure safe use (ETASU) - interventions to reduce risk
e implementation system - monitoring and evaluating ETASU
The drug sponsor implements some or all of these measures to educate prescribers and
patients and to monitor the safety of their product. The most rigorous REMS
component is ETASU, which may restrict the usage of the drug to certain patient
populations or require more stringent monitoring. The incentive for REMS adoption is
to enable products with questionable safety implications to be available sooner for
patients who could benefit from them.
2.6.2 Label
The drug label is a critical component of the NDA, as it contains specific information
about how the drug is to be used, as well as any known adverse effects. All of the label
information that gets submitted to the FDA for an approved drug is provided publically
on National Library of Medicine's (NLM) DailyMed website. A screenshot for the
cancer drug Avastin from DailyMed is shown in Figure 22.
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AVASTIN (bevacizumab) injection. solution
[Genentech, Inc.] Review RxNorm Normal Forms
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Initial U.S. Approvah 2004
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not adadmister Avasd to padents with surios heaorrhage or resant henuptye. (53)
Figure 22: Screenshot of Avastin Label from DailyMed
(NLM, 2012)
The manufacturer, or drug sponsor, uses the data collected through the development
process to create the label. The FDA must approve the label contents, as this is the
most widely used dataset describing the drug that is available to the public. The
contents of the label include:
Figure 23: Data Contents in a Drug Label
(NLM, 2012)
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During clinical trials and interactions with patients, manufacturers collect patient
reported data that is used to prove the labeling claims. Patient reported outcomes
(PROs) are patient psychometrics collected on questionnaires during clinical trials. The
subjective data pertains to symptoms, health status, general health perceptions, and
health related quality of life (HRQoL). These data points are direct patient reported
measurements of physical, psychological, and social observations and are used to
supplement the other data collected during a clinical study.
2.6.3 Adverse Events
During clinical trials, several pieces of data are collected when an adverse event is
experienced including duration, severity, laboratory abnormalities, action taken, and
outcome. In order to be able to record adverse events after a product is
commercialized, the FDA has a passive adverse event reporting system, FAERS.
Adverse event reporting is voluntary and open to anyone through the FDA's MedWatch
website. Clinical reviewers at the FDA will regularly scan the database and assess for
new safety concerns, which may result in regulatory action including updating the
label, restricting drug use, or recalling the product. Adverse event reporting is an
important feedback mechanism, although the quality and volume of the data does not
make it a sufficient safety monitoring system (Heinrich, 2000).
2.6.4 FDA Data Resources
The FDA, and other regulatory bodies, maintain a lot of data about medical products
and make several resources available to the public. A typical drug profile on the FDA
website contains the following pieces of data.
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Figure 24: Data Elements for Drug Available from FDA
Additionally, the FDA maintains several databases on approved drugs and
corresponding safety. These data sources are maintained and useful in capturing
detailed information on drugs and other medical products.
Drug Approvals and Databases S
Adverse Event Reporting System
(AERS)
Approved Drug Products with
Therapeutic Equivalence
Evaluations (Orange Book)
Bioresearch Monitoring Information
System (BMIS)
Clinical Investigator Inspection List
(CLIIL)
Dissolution Methods Database
Drug Establishments Current
Registration Site
Drugs@FDA Database
Inactive Ingredient Search for
Approved Drug Products:
Frequently Asked Questions
National Drug Code Directory
Postmarket Requirements and
Commitments
Approved Drugs
Drug Alerts and Statements
Importing Prescription Drugs
Medication Guides
Drug Safety Communications
Drug Shortages
Postmarket Drug Safety
Information for Patients and
Providers
Information by Drug Class
Medication Errors
FDA Drug Safety Newsletter
Drug Safety Podcasts
Safe Use Initiative
Drug Recalls
Drug Integrity and Supply Chain
Security
Multistate outbreak of fungal
meningitis and other infections
Figure 25: List of Resources Available on FDA Website
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Regulators must coordinate closely with manufacturers to ensure that the data
published accurately characterizes the medical product and is understandable to
providers and patients. Regulators rely on the data supplied by the manufacturers to
make crucial decisions about product licensing. The data flows from the patients, to
the manufacturer, to the regulator, and finally to the public. Along the way, the data is
summarized and reformatted, based on the manufacture selection process and
guidelines enforced by the regulators.
2.7 Distributor Data
Distributors source data from the manufacturers and regulators, and provide data to
the payors for product reimbursement. Before distributors, such as PBMs, can offer a
medication to patients, pharmacies or hospitals, the product needs to be approved and
added to their formulary. The PBM will then negotiate the price with the manufacturer
and also coordinate fees with the different distribution channels. The PBM network in
Figure 26 illustrates the product flow through various distribution channels and
corresponding payment considerations.
PREMIUMSWA - - -
H
T OF MAUACTURE REBATES
AYMENT ADMIN -HARMC CLAMS PROCESIG
-NEGOTIATE NETWORK DISCOUNTS
DISPENSING FEESCOA EN
NEGOTIATED PRIE PHRAY ML00 RSRPIN PATIENT'S HOUSE
FLAE ON NEGOTITED
Figure 26: PBM Network
(Andrew, 2009)
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The drug pricing data is a driver for the PBM network, as drugs will vary in price
depending on the payor and type of distributor - mail order, retail pharmacy, etc. As
well, drugs are typically categorized into three tiers, defining the patient copay range,
with the most expensive drugs being tier three. These are typically non-formulary
brands, while tier 1 is generics, and tier 2 is brand drugs on the formulary. Other
pharmacy administrative data is listed in the second column of Figure 27.
PatientAdmininfo
SocialSecurityNumber
DriverticenceNumber
Memnberidentification
AccountNumber
Contactinfo
Name
Address
Telephone
Demographics
DOB
Gender
ZipCode
Race
Ethnicity
PaymentMethod
Bankinfo
CreditCardinfo
Authorization
Signature
PharmacyClaim
Druginfo
DrugCode (NDC)
DrugName
PrescriptionInfo
Number
Dte
New/Refilli
DosePerDay
DaysSupply
Quantity
Strength
Generic
FormularyCode
RouteOfAdministration
Natureofillness
Nature0finjury
Pharmacyinfo
PharmacyName
Pharmacyldentification
PharmacyAddress
PrescribinigPhysicianinfo
PurchaseDate
costs
ChargeAmount
CoPay
Reimbursement
PharmacyAdmin
NatlonalDrugCode
Formulary
Tierl
Tier2
Tler3
Prices
CoPayment
AdministrationFee
ManufacturerRebate
FlatDiscounts
PerformanceDiscounts
CombinationDiscounts
DispensingFee
AverageWholesalePrice
MaximumAllowableCost
UsualCustomaryPrice
Pharmacyinfo
MallOrder
RetailPharmacy
Specialty
DruginfoResources
Primary
PharmacyJournals
MedicationGuides
DrugLabel
Secondary
Medline
PubMed
Cochrane
lnternationalPharmaceuticalAbstracts
Tertlery
DrugFactsComparisons
AmericanHospitalFormularyService
USPDispensinginformation
DrugInformationHandbook
RedBook
Micromedex
ClinicalPharmacology
Lexi-Comp
Medscape
Figure 27: Categorization of Distributor Data
(Ambizas, Ezzo, & Patel, 2009)
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Every drug approved in the United States by the FDA has a unique ten-digit drug code,
or national drug code (NDC). The makeup of the number identifies the labeler,
product, and package information for a specific drug. The labeler is the manufacturer
or distributor of the drug; the product code identifies the strength and dosage; and the
package code signifies the package form and size (FDA, 2012d). NDCs can be queried
on the FDA website, under the national drug code directory.
Payors contract with PBMs for prescription services. The distributor therefore initiates
all the data within the pharmacy claim. As described in the payor section, this data
includes the drug or product type, prescription number, dosage, and price, as well as
patient identifiable information. The distributor also has the patient's contact
information, account numbers, and credit card information used for purchases. PBMs
track patients' entire prescription histories; recording prescriptions filled from various
prescribers and picked up at different distributors (polypharmacy). This data is helpful
in indicating drug interaction oversights or prescription drug abuse. The refill record
also gives clues to medication adherence, and PBMs are now using this data to predict
patient compliance and behavior.
The fourth data category of distributor data is the drug information resources.
Distributors are often in direct contact with patients and need to supply medication
guides and other information about the drug. Medication guides are included with
several prescription drugs and must be distributed to the patient, when required by the
FDA. These guides inform the patient of the instructions for use and describe the
possible side effects and safety considerations. Distributors also maintain data about
the drugs they distribute, and source this from released information from the
manufacturer and journal published clinical trials. Additionally, there are many online
resources for drug information that pharmacists use, including the United States
National Library of Medicine's MEDLINE/PubMed, Redbook, and the FDA.
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Similar to medical claims data, PBM data is also being repurposed, again due to the
volume and availability. Several companies are using pharmacy data to gain insight
into provider prescribing habits, as well as drug utilization and trends. These types of
reports are sold to pharmaceutical companies for strategic marketing purposes. As
well, insurers use this data during the underwriting process to verify a patient's
application and eligibility for a plan based on their prescription history. Insurers can
also identify risk using the types of medications recorded. Milliman and Optum Insight
are two companies that buy PBM data that includes patient specific information, and
sell the reports to payors for underwriting.
As previously discussed, pharmacy data is also being used to make predictions about
patient behavior and clinical outcomes - identifying overuse, underuse, drug safety,
and medication gaps. The intent for these analytic measures is to reduce cost and
improve outcomes through clinical recommendations.
Similar to the ACPD, the prescription drug monitoring program (PDMP) is a statewide,
government-administered electronic database that collects specific information about
prescriptions filled for certain types of pharmaceutical drugs (Privacy Rights
Clearinghouse, 2012). In this way, prescription drug usage for an entire population can
be analyzed. The data collected by the PDMP is currently being used to monitor drug
diversion and abuse for controlled substances. Depending on the state legislation, this
data can be transferred to law enforcement for surveillance.
The data collected and managed by the distributor spans across several stakeholders.
As manufacturers release drug specific information, distributors assess the clinical use
of the drug and determine whether it should be added to their formulary. This data is
then passed along to other distributors, payors, providers, and patients. The
distributor is the intermediary between the product and patient, so the quality of the
transferred information greatly impacts the patient experience. Finally, the wealth of
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patient pharmacy data has led to a greater understanding of medication usage, which
is currently being used for passive monitoring of prescription drugs.
2.8 Data Landscape Summary
The exploration of data from the lens of each stakeholder presents a view of the health
system with over 500 different kinds of data. This data is scattered throughout the
subsystems and the meaning varies depending on the beholder's perspective. For
instance, data from the payor point of view is claims based, relying on standard codes
to describe clinical status. Whereas data from the manufacturer point of view is
product specific and needs to characterize disease therapy and report actual clinical
effects. As a result, there is no single way to define data in health.
Through discussion of each stakeholder, we begin to examine how the data flows
through the system. The transactions that occur between the stakeholders define the
direction of flow. Some of the data transfers among subsystems, but is fragmented or
represented in different forms. Other data remains within its silo and is used only by
its originator. We also observed that when an abundant of data is available in a
standard format, it is being repurposed. Both medical and pharmacy claims data are
being used for different purposes than originally intended. Data in the health system is
dynamic and the response of each stakeholder greatly impacts how it is utilized.
The data defined in this chapter is used for subsequent analyses in this thesis. Chapter
3 explores alternate methods to organize the data in order to further the evaluation
and gain a deeper perspective of data in the health system.
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CHAPTER 3: ANALYSIS OF HEALTH DATA
In chapter 2 we present the data landscape through the lens the stakeholders. The
stakeholders provide a convenient means to identify data, but fail to inform the system
perspective for data. In this chapter, we view data beyond its stakeholder origin
because we believe in order to understand the system we need to examine data as a
whole. We take a three-tiered approach to deconstruct the system, looking at
communication flows, defining data dependencies, and assessing system flexibility
through data attributes.
Our analysis reveals that there is no single perspective to understand data. The
limitations we observe suggest that the best approach to view the system is with a
combination of methods - resulting in the patient interaction data flow diagram
discussed in chapter 4.
Table 4 summarizes the main methods and tools we used, how we used them, and the
observed limitations. We review some of these methods in the rest of the chapter.
Method / Tool How we use it Observed limitations
Adjacency matrix / illustrate kinds of data that does not show sequence of
Excel, transfer between transactions, represents only
Network diagram / stakeholders and direction high level communications, does
yEd of communication not define data usage
Dependency define significance of indirect
analysis / upstream/downstream influences, complex relationships
Design structure influences and prevent precise dependency
matrix (DSM) dependency clusters definition
Attribute analysis / link data to characteristics, lack sense of data usage and
Visual visualize unconventional flow
understanding clusters
environment (VUE)
Value assessment define purpose, value, and relationships across data not
/ Excel use of data to determine captured
gaps
Data flow map data flow during a represents general data
diagramming (DFD) patient's interaction with categories, individual data types
/ yEd, ch5 the health system are implicit
Object-process verify system properties not intuitive to derive, need to
modeling (OPM) / that result from DFD translate from health terminology
yEd, ch7 analysis
Table 4: Assessment of Methods and Tools Used to Analyze Data
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3.1 Cross-Stakeholder Communication
As a first level of analysis, we start by looking at the kinds of data that transfer between
stakeholders. This defines the first order, or highest level, of communication. Figure
28 shows, as an adjacency matrix, the data flow from the stakeholders in the column to
the stakeholders in the row. For instance, the manufacturer communicates product
information to the regulator during the commercialization process. The kinds of
communications are categorized by type, indicated by the different colored cells: raw,
informative, standardized, and inferred.
LEGEND: nmunication
Figure 28: Adjacency Matrix for Cross-Stakeholder Communication
The types of communications are categorized in the legend. Raw
data is communicated directly from its source; informative
provides description, explanation, or education; standardized
indicates policy or regulation; and inferred data is used for
secondary communications.
Adverse events are differentiated, as the communication is event
dependent, and not considered standard flow.
To ease interpretation of data flows, the adjacency matrix may also be represented as a
network diagram (Figure 29).
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Figure 29: Network Diagram of Data Flow between Stakeholders
Reference legend in Figure 28. This diagram shows the kinds
of communication and the direction of flow. As illustrated by the
red lines, the raw data derives from the patient correspondence
with the provider and payor. The dashed lines of raw data
indicate intermittent transfer, and based on the reported
adverse events rate, this occurrence is quite low. The blue
lines indicate the informative data transfer given by the provider
to the patient as treatment recommendations or through the
product and label data transfer by the manufacturer. The green
lines indicate the patient specific data that is standardized into a
claim or coverage plan. These pieces of data have partial
information about the patient but the transfer between
stakeholders is automated, or follows an existing protocol. The
yellow lines indicate inferred data, or data that flows through a
secondary function. For example, the distributor gleans
provider-prescribing data from the prescription record, and can
analyze patterns for monitoring. This data may also get
transferred to the manufacturers and used as marketing input,
as previously discussed in section 2.7.
The adjacency matrix and corresponding network diagram help us to evaluate the
stakeholder data defined in chapter 2. A takeaway from this analysis is that the patient
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coverage 
0
producti
safety
and manufacturer are the main sources of data and most of the other communications
are data transfers downstream. Referring to Figure 29, the red and blue arrows
indicate these two types of upstream communications, while the green and yellow
arrows indicate the downstream communications. Another takeaway is the instances
where limited or no communication transpires between stakeholders, as with payor to
manufacturer and regulator.
These adjacency matrix and network diagram are useful in understanding the highest
level of communication between the stakeholders. We define the kinds of data used
for communication and the direction of flow, and further categorize communications
by type. This representation does not yet show the sequence of transactions or data
usage. We address these limitations in the following sections.
3.2 Dependencies
We use DSM to reveal the dependencies amongst the 17 first order communications,
selected for the adjacency matrix in section 3.1. DSM is a structured method to
evaluate and visualize dependencies. We plot the selected data onto the DSM to
determine the dependency of each communication to the next. At this stage of the
analysis, only the direct dependencies are considered and indicated along the vertical
column for each kind of data - the data in the rows are inputs to the data in the
columns. Partitioning the matrix sorts the rows and columns by dependency clusters
(Figure 30).
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30: Partitioned DSM of First Order Stakeholder Communication Data
The application of DSM to the kinds of communications between stakeholders reveals
three dependency clusters. The first cluster groups data produced during product
licensing that directly influences treatment decisions and adverse events. The other
two clusters are administrative including claims, benefits, and product price data.
Treatment data is the most dependent data type with nine inputs, including product
information, patient benefits, and reported symptoms. Adverse event data is next with
five inputs. Both treatment and adverse events share dependencies on product, safety,
and label, and system data.
The three empty columns on the right - enrollment, symptoms, and financial - are data
sourced directly from the patient and therefore have no input from the other
stakeholders. These components of patient data are used to inform six other data
types (bottom three rows) indicating the wide usage of patient data.
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Moving from communications across stakeholders, we go one level deeper to examine
dependencies at the level of content, not just at the level of communication. We
consider the main kinds of data managed by each stakeholder defined in chapter 2.
Figure 31 shows the selection of contextual data that we use in our expanded DSM.
This data matches the subcategories of data from the figures and tables in chapter 2.
Figure 31: 60 Selected Subcategories of Data from Chapter 2
(Data sourced from Figure 6, Figure 7, Figure 13, Figure 27, and Table 1)
In assigning dependencies across the data subcategories, we rely on the description in
chapter 2 to resolve any ambiguities about the nature of the data or meaning.
Additionally, we only consider the dependencies that reflect mainstream usage. We
also decided to differentiate between direct, indirect, and possible future
dependencies, as shown in the DSM in Figure 32.
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Figure 32: Non-partitioned DSM of 60 Data Subcategories
Legend:
1 = direct dependency
2 (yellow) = indirect/partial dependency
3 (blue) = possible future direct dependency
Figure 32 shows the adjacency matrix before application of the partitioning. We show
this figure to highlight some of the non-direct types of dependencies - indirect, partial,
and possible future dependencies that indicate subtleties in defining the dependencies.
There are several indirect influences: cost of coverage is dependent on a patient's
coverage plan and is indirectly influenced by the cost of services and drug price. As
well, published studies and journal articles indirectly influence treatment and
prescription selection. We considered several more relationships when assigning the
dependencies.
Figure 33 shows excerpts from the partitioned DSM expressing only the direct
correlations, after removing the level two and three dependencies. Refer to Appendix
C for the full plot of the DSM.
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Figure 33: Partitioned DSM of 60 Data Subcategories, Direct Dependencies
The expanded DSM confirms our observations made with the dependency analysis of
the communications between stakeholders (Figure 30) and adds further detail. For
instance, although there are several data inputs into the medical record, its influence
downstream is limited. The medical record has only one downstream direct influence
(diagnosis), but has 14 dependencies. This suggests that when the patient symptoms
and other 13 data types are recorded in the medical record, the flow stops - there is no
other data category that requires input from the medical record. Consequently, the
medical record is only used for provider management of clinical data. Furthermore, the
medical claim is dependent on the diagnosis and procedure codes inputted by the
provider, but not dependent on the medical record. This suggests payor inference of
clinical status using claims (section 2.4).
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The cluster on the bottom right corner shows interdependencies with drug
development and regulator data. Although the approval history, drug label, and
adverse events all have downstream influences to diagnosis and treatment decisions,
the bulk of the data does not correlate to the care system, even though similar data
types (patient data collected during clinical trials) are shared between the two
segments. We interpret this lack of dependency a result of two subsystems - one for
care and one for product development - that are loosely connected. The impact is two
disparate systems that have no standard flow for communication or feedback.
DSM is valuable for assessing dependencies on a subset of data and identifying clusters
that suggest tight correlation, although it has shortcomings. The challenge of
preciseness of the dependency definitions is a result of the faint relationships between
discrete data types and abundance of indirect and partial correlations.
We now understand communication flow and data dependencies. In the following
sections we look more closely at the data characteristics and usage in the system.
3.3 Attributes
We categorize data by its attributes to assess the nature of the data and relate kinds of
data that are otherwise not relatable. Attributes tells us the dynamics of the data,
availability, and constraints imposed on the data, all of which affect how the data is
used - or can be used - in the health system. Categorizing data by its attributes
delivers a descriptive assessment of the data as a whole and reveals unconventional
clusters. In this section, we explore alternate uses of the data, outside of its current
domain of use. We select a collection of non-related data from the various stakeholder
categories in chapter 2. Based on the characteristics of the data, the following
attributes are defined:
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static not changing, always true
real time immediately viewable dynamic data
controlled hypothesis driven protocol
uncontrolled not following standard protocol, random, real world
open publically available, online
closed private, protected under HIPAA
documented standard within the health system
undocumented outside of the health system
preventative informative health information to protect and prevent
chronic management repeated data for same condition
patient independent general health and disease information
patient dependent patient specific data
Table 5: Sample Attribute Categories
We link each kind of data to its corresponding attributes. The attributes are shown as
ellipses on the map in Figure 34 and attribute pairs are shown in the same color. The
rest of the nodes are the different kinds of data, drawn from the stakeholder sections
in chapter 2.
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Figure 34: Data Attribute Map
This analysis is useful in identifying connections between otherwise unrelated kinds of
data. For instance, adverse events caused by medical products and patient blogs are
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public forms of data. Although it has not been conventional to relate these types of
data, adverse event data could be gleaned off of patient blogs and other peer-to-peer
health discussions, presenting an opportunity to use social media to supplement safety
reporting systems (FAERS). AdverseEvents, Inc. is an online service that collates
adverse event data and claims that actively monitoring social media and other online
outlets can portray a more accurate view of drug safety (Overstreet, 2012). Even
though this correlation does not originate from an existing stakeholder, it presents an
opportunity to use input collected online to inform product safety.
There are several other examples of new correlations that we make from the attribute
map that present opportunities for data usage beyond its original domain. For
instance, some of the kinds of data that could inform care decisions are undocumented
and uncontrolled, meaning use in the care system is not well defined. These include
behavior, symptoms, vital trends, and medication usage. Collection of this data resides
outside of the traditional clinical environment, and therefore are not typically
documented or used for decision-making. Various trends in wearable monitors and
device technologies make data collection at the patient feasible and are discussed in
section 5.1.
The open, undocumented, and uncontrolled attributes indicate that there are clusters
of data that are not formally tracked in the health system, resulting in fragmented data
usage. Some of the kinds of data that share these attributes are represented in the
lower half of the map in Figure 34. The system concept that is presented in chapter 6
considers the entry of these kinds of data into the health system.
3.4 Value Assessment
We determine the value of the data by assessing its purpose and how it is currently
being used in the health system. We compare the value we believe the data to hold,
based on stakeholder interviews and analysis of the literature, to how the data is
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currently being used. The gaps observed indicate that the data has more potential
than what it is currently being used for, presenting opportunities for improvement.
We evolve the stakeholder categories into seven, more functional, categories, shown in
the first horizontal row in Table 6. For each category we list representative examples
of data from chapter 2, describe the purpose of the data, value of the data, and how
the data is currently being used.
CATEGORY of DATA
6
Product
Science Treatment, Drug, Clinical Real World
A Pre-Clinical Clinical Research Therapy, Device Reports/Records Administrative Clinical Patient Owned
chemistry dinicaltrials lab data subjectivenotes recrd of encounter epidemiology studies behavioral data
disease biology protocol design structured behavior symptom time sequence patient registdes perceived symptoms
pharmacology demographics label physiological metrics procedure codes surveys physiological metrics
EXAMPLES ADME dose schedule Instructions lab results diagnosis codes surveillance genetic
toxicology statistics interactions scan results treatment codes safety reports online resources
outcomes adverse events medications pharmacy records social communities
behavioral data side effects treatments cost / payment
pre-clinical research safety, efficacy, manage/inform medical record financial transactions disease analysis patient management
PURPOSE effectiveness of treatment post keeping per patient of own health
B of DATA therapy on disease diagnosis
compound measure of benefit to safety warnings & population health
investigation risk contraindications management
VALUE of human health primary: patients guides treatment summary of administration view of disease patient self-
C DATA with disease individual's medical efficiency population knowledge
disease treatment secondary: informs safety convenience for real world'outcome, support networks
manufacturer 101 providers feedback
HOW IS drug discovery product licensing decide treatment manage patient care primary: process statistical reports patient knowledge
D DATA reimbursement
benefit-risk analysis may bias diagnosis secondary: cost- hypothesis patient reported
effectiveness of care generation outcomes
WHAT IS chemistry/genomics patient level analysis, patient level analysis relationship to other benefit-cost analysis patient level analysis relationship to others
E MISSING? of target patients feedback patients
C - D
Table 6: Data Value Analysis
The final row in Table 6 indicates the missing information when the value of data is
compared to how data is being used today. We analyze the missing information and
formulate our results in Table 7. This gap assessment is an important takeaway from
the value analysis as it presents the specific losses of data and their impact on the
current system.
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1 2 3 5 7
Limited individual patient (chemistry, genetic) data in
the current drug discovery process may result in
ineffective roducts for the tarnet population.
Outcomes from today's clinical trials only inform
benefit-risk for the pre-selected patient group, limiting
learning for other patient types.
Available products may bias diagnosis, even with no
knowledge of an individual's response to a selected
ied therapy.
Toduay's medical records are limited to individual
patient management, as correlation among records
does not exist.
Administrative records (claims) are unidirectional with
limited outcome data; therefore valid cost-benefit
cannot be assessed.
Data collected from today's real world studies/events
has limited use: assumptions made on general
population, unknown denominator, and questionable
reliability.
Data sourced from the patient is subjective, often
unreliable, and has vast entry possibilities into the
health system, making it difficult to compare among
patients.
Table 7: Results of Data Value Analysis
Several of these hypotheses are referred to in other sections in this thesis, but here are
specifically presented as the result of our value analysis.
Another way to analyze the value of data is to assess the comparability and usefulness
in providing feedback to the system. Table 8 looks at the same categories of data from
Table 6 and assesses whether the data is specific to the patient, can be compared, and
whether it can be used to provide feedback.
Table 8: Qualitative Assessment of Function for Selected Data Categories
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First, we observe that the data that is specific to the patient is difficult it is to compare.
This implies that learning from one patient to another is limited and not a function of
the current EHR system. Second, the data that already has standard transfer paths and
protocol is most comparable, namely clinical research, product data, and
administrative data. Claims data, for instance, has nationally approved formats using
sets of coding standards, making it ideal for comparing (section 2.4). Thirdly, we
observe that feedback is limited to data generated from patients and real world
studies. Based on the results in Table 7, both of these data categories have limited
value, although currently are the main source of feedback in the system.
The methods we use to assess the value of data helps to logically describe the
inefficiencies in the current system. The result is a series of hypotheses that are driven
by how data is being used today compared to its potential use. This analysis reveals
opportunities for enhanced data use.
In this chapter we have uncovered several vantage points to understand the system
and visualize data beyond its stakeholder origin. We conclude that there is not a single
method that encompasses all of the insight needed to assess data as a whole. Rather,
we combine elements of the different approaches to arrive at a representation that we
can use to evolve our thinking of how data flows in the system. This representation is
the patient interaction data flow diagram, discussed in chapter 4.
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CHAPTER 4: PATIENT INTERACTION DATA FLOW
The methods used to analyze data in chapter 3 are effective in understanding and
visualizing data usage from the perspective of the stakeholders that generated it;
through communication, dependency, attributes, and value of their data. However,
the stakeholder analysis does not inform how data is used to further the objectives of
the system. In this chapter, we address that by assuming the perspective that the
patient is the ultimate source of data and interpreting data flows to and from patients,
as they interact with the health system.
4.1 Data Flow Diagram
Data flow diagramming (DFD) is a method used to express the structure and flow of
data. We combine our understanding of the data in the health system with the process
modeling rules of DFD to create the patient interaction data flow diagram in Figure 35.
The diagram defines the types of data, where the data interfaces with the system, and
how the data impacts processes and decisions. Fragments of data combine to inform
provider diagnoses and intervention selection, and fragments of data break away from
the main flow during transactions among the system actors - during payor
reimbursement and product licensing.
The patient interaction diagram provides the foundation for a systematic analysis,
defining the logical data flow and also identifying instances where flow is interrupted.
The data losses that occur when the flow is interrupted can be used to identify system
inefficiencies and opportunities for improvement.
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Figure 35: Patient Interaction Data Flow Diagram
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The shaded regions in the diagram indicate the three interaction phases: examination,
diagnosis, and intervention. Each phase reveals a scatter of input and output data,
denoted by the red parallelograms. The following two sections describe the forms of
data, and the subsequent sections discuss the impact of observed data loss, when
partial data is used for decision-making.
4.1.1 Input Data
The input data feeds into the system at process and decision nodes and is used to
execute processes and inform decisions. This input data is truly an assortment of data
fragments; for instance, the patient's clinical history, patient provided symptom
descriptions, administrative data regarding coverage policy, and the knowledge and
experience of the provider all drive the examination phase. Other forms of input
among the phases are non-patient specific data, such as publications, journal articles,
organizational experience, and standards in science and medicine. There is no
standard collection of input data for all patients and therefore the basis for decision-
making varies widely from patient to patient. This posses a challenge to learning:
variance across input data can be expected to translate into increased variance
throughout the system all the way into the outcomes. However there are no
mechanisms to capture lessons that would help reduce said variance.
4.1.2 Output Data
The data outputs are clinical or administrative. The gray-shaded data elements in the
interaction diagram identify the clinical outputs at the point of care: examination data,
test data, and intervention data. These are patient-specific and include physiological
measurements, diagnostic results, and observations of patient state. The clinical
output data are stored in a patient record and are used by providers to inform patient
care and decision-making. During interactions with the same provider, the patient
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record is enhanced with new forms of data, which may be further collated into an EHR
(section 2.2).
Patient-specific administrative output data are derived from the contents of the clinical
record. As described in section 2.2, reasons for visits, diagnoses, and interventions all
have standard codes. The reimbursement claim, submitted to the payor, consists of
the best available codes for each patient interaction. These claims are in each phase of
the interaction diagram: interaction claim, procedure claim, and prescription claim
(shaded in green).
Referring to interaction diagram, the right-hand section of the intervention phase
describes the data flow during clinical research. Here, the clinical output data is driven
by the trial protocol and is similar in content to the EHR, although more structured.
Discussed in section 2.5, the clinical data for drug research is stored and managed in
the trial CRF (case report form) that is used by the regulator during the approval
process. Once a product is approved to market, the manufacturer releases product
and safety information (denoted on the interaction diagram as label, and publications)
that is considered an abbreviated summary of the clinical studies. This output data
becomes input for provider intervention selection.
Communication between stakeholders is when flow is interrupted and data loss occurs.
The following sections overview some examples of the impact of decisions based on
partial information.
4.1.3 Communication Between Provider and Payor
The purpose of a claim is transactional. It does not contain clinical data or patient
history, but rather is a record of an interaction. It is therefore arguable whether the
claim is clinically meaningful and should be the mechanism used to determine care.
For instance, payors review claims against insurance policies and standard procedures
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and either approve or deny reimbursement. This is illustrated in all three phases of the
interaction diagram and occurs either before (prior authorization) or after services is
provided. The payor reimbursement decision has a strong impact that could result in a
different medical course or early termination of care, having tremendous effect on the
patient outcome.
4.1.4 Communication Between Manufacturer and Public
The product data in the interaction diagram represents the safety and efficacy data
generated by medical product manufacturers during development and licensing. (Refer
to section 2.5 for a complete list of product data). The purpose of this data is to satisfy
regulatory requirements in order to grant approval to market, and once approved, only
a subset of this data - expressed in the interaction diagram as price, label, instructions
for use, and publications - is made available to the other stakeholders. Providers use
this information to select interventions, payors to assess cost-benefit, and patients to
research treatment options. The information only includes population statistics
derived from the clinical studies which is hard to relate to the needs of a specific
patient.
4.1.5 Communication Between Patient and Provider
Patients are data rich. However, the data collected during the provider interaction
(examination data, test data, intervention data) is only a snapshot of the patient's
clinical state, and may not always be sufficient to understand the entire clinical profile.
Measurements taken at the point-of-care do not often reflect the normal patient state,
nor are single data points effective to manage chronic conditions. Blood pressure,
blood glucose, electroencephalography (EEG), electrocardiography (ECG), and like data
can all be monitored outside the clinical environment, between patient interactions
with providers, dramatically enhancing the data pool used for diagnosis and
intervention.
76
Trends of remote patient monitoring (RPM) merge wearable sensors with wireless
technology. Remotely collected data is transmitted to patient EHRs and decision
support algorithms alert providers. Several examples of remote monitoring devices are
listed in section 2.3.2. Other benefits to monitoring patients in their natural
environment are reduced cost, reduced hospitalizations, continuous care, and patient
engagement. See section 5.1.1 for a continuation of this discussion.
The entry of patient sourced data at the top of the interaction diagram indicates that
the patient drives the entire flow of processes and decisions. The accuracy of
diagnoses and effectiveness of interventions rely on the collection of input data. The
provider's decision of what data to collect also makes a large impact on the care path.
The selection of patient data that is used during patient-provider interaction - whether
sourced within or outside the care system - greatly affects the clinical decisions made
after the first encounter.
4.1.6 Communication Between Providers
Patient information maintained by one provider might not transfer to other providers,
either through referrals or upon transitioning to different care systems. The result is a
suboptimal starting point for care. Referrals occur between primary care physicians,
secondary specialists, and tertiary care. (Gandhi et al., 2000) shows that
communications between providers lack clarity about the reason for referral, have
inadequate clinical notes, lack timeliness, and have unclear follow-up plans. This
breakdown in data flow leads to poor continuity of care, delayed diagnoses,
unnecessary testing, and risk of polypharmacy. In addition, complexity of health care
plans and payor approval delays further strain the communication channel.
Data sharing at the interface of the phases among providers exemplifies the goals of
the accountable care organization (ACO) model. ACOs claim to achieve better
communication among providers by coordinating a care team network for each
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patient. This collaboration is believed to enable data sharing among the providers who
treat a patient.
Other instances of data flow between stakeholders are sparse, also observed in the
adjacency matrix in chapter 3. A failsafe interaction that is not represented on the
interaction diagram occurs during unexpected patient events. For instance, patients
and providers may provide data to the manufacturer or regulator when an adverse
event is experienced. Most regulatory systems have a mechanism to enable voluntary
adverse event reporting (FAERS, MedWatch). This provides additional input data into
the regulatory system, but does not alter the main flow. However, the value of these
reporting systems are limited since less than 10 percent of adverse events get reported
(Goldman, 1996).
The interaction diagram is used to show how data is being used at the point of care to
treat symptoms. The decisions that are made at each node have great impact on
patient outcome, but are only as good as the data that feeds into them. We observe
interruptions of flow throughout all of the interaction phases and specifically among
the interfaces between the stakeholders. Instances of data loss or missed opportunity
for data usage are revealed as we consider the communication between stakeholders.
In the next chapter, we discuss the trends that aim to improve data usage and assess
their impact on data flow.
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CHAPTER 5: DATA DRIVEN TRENDS
The interaction diagram we introduced in chapter 4 defines the flow of data that
emerges from the patient's interaction with the health system. There we observed the
natural tendency of the system design to fragment and silo data. In this chapter we
focus on the solutions that are emerging to overcome difficulties associated with lack
of data at different stages of the system. We inventory existing companies, initiatives
and technologies that propose data empowering solutions throughout the system.
When these solutions are overlaid onto the interaction diagram (Figure 36) they map to
the inefficiencies identified in chapter 4. The ability for each solution to be
represented by a category on the interaction diagram validates the diagram and shows
a broader system problem - data driven solutions are local. That is, the space of
solutions is as fragmented as the data itself. Local solutions address local inefficiencies
but fall short of addressing the flow of data at the system level.
The emerging categories of data driven solutions are labeled A-I in Figure 36 and are
further described in Table 9. The 9 categories arise from analysis of over 100 industry
trends, of which 40 are shown in the example column of the table. Each of these
examples addresses a local opportunity for improvement in data quality, clinical
outcomes, health care costs, or process efficiency. Some of the trends are incremental
improvements driven by the incumbents, while others are divergences propelled by
new technologies.
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Figure 36: Data Driven Trend Categories A-1 Mapped onto Interaction Diagram
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Table 9: Description and Examples of Data Driven Industry Trends
Discussion of Data Driven Trends
5.1 System Input (A)
Patients now have the ability to record their vital signs, discover their DNA, and
research their symptoms before ever stepping into a physician's office (section 2.3).
This information is indirectly entering the clinical environment through a narrow
interface that relies on the discretion of each patient and provider. The result is a
breadth of new data that does not yet have a standard entry path into the system or
developed protocols for interpretation for clinical decision-making.
5.1.1 Wearable Sensors
The wearable sensing device market is forecasted to be a $6 billion industry by 2016
(Ahadome, 2012), indicating the need to measure physiological signals outside of the
care system. There are over 20 physiological measurements that can be recorded using
a wearable device (Table 1) and the data is used to track health indicating metrics.
Figure 37 shows examples of some of the companies that market these devices.
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Figure 37: Vendor Landscape for Wearable Technology
(Ahadome, 2012)
The majority of these wearable sensors is available direct to consumer and has a broad
range of applications, from weight loss to sleep management. Companies that intend
for the data retrieved off of their devices to be used to inform clinical decisions must
obtain medical device clearance (through the FDA in the United States). The regulatory
requirements force the suppliers to narrow the domain of application and provide
explicit protocols on device functionality and intended use for specific diseases or
medical conditions.
For instance, Valencell, the producer of the biometric earbud PerformTek TM , has
announced plans to pursue FDA approval for clinical management of hypertension and
diabetes ("Valencell - Health Management," 2013). Currently, PerformTekTM is
positioned as a consumer device used for fitness training that feature an earbud
technology that continuously measures heart rate, respiration rate, metabolic rate,
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VO2max, and ventillatory threshold. Since vital measurements in the ear are highly
accurate, PerformTek TM is well positioned for medical device status if the data proves
its use in managing targeted conditions - narrowing its application scope for regulatory
purposes.
Once considered a medical device, the product may be prescribed and the data is
accepted to use for clinical support. Since this is suggested after patient-provider
interaction, this data is no longer characterized as system input and becomes feedback
data, which is discussed later in section 5.9.
5.1.2 Direct to Consumer Genetic Testing
Direct to consumer genetic testing is forecasted to grow well over $200 million over
the next five years. 23andMe, deCODE genetics, DNA Direct, and GeneLink Biosciences
are examples of companies that are leading this segment - providing test kits that can
be purchased online for a relatively low cost. In some cases, the resulting data is
helpful in discovering individual characteristics that relate to disease risk, drug
sensitivity, and carrier status ("Genetic Testing for Health, Disease & Ancestry; DNA
Test - 23andMe," 2012). The various vendors are also using consumer data for
research. This data is being collected outside the care system, and in order to be used
for clinical decision-making, must be narrowed to specific applications.
5.1.3 Online Resources
80% percent of internet users in the United States look online for health information
(Fox, 2011). People seek answers to health questions, consult reviews of treatments
and physicians, and connect with others with similar conditions. WebMD and
MedicineNet are examples of online resources that provide detailed medical
information and supportive communities to supplement professional care visits.
Access to social media and peer networks influences the patient's entry point into the
health system, affecting when and where care interactions occur.
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These three examples demonstrate the opportunities for collecting data outside of the
clinical care setting. The data is being used at the patient level for individual
assessment, which is enabling patient engagement. There is concern, however, about
quality, opportunities for misusing, and confusion that are inherent with direct to
consumer health products and online information.
Patient sourced data is not considered as typical system input, as it lacks a standard
path into the system. As well, the broad applicability of many of the sensing devices
and genetic testing limits the use in the clinical environment.
5.2 Clinical Knowledge Warehouse (B)
Several applications are now used at the point of care to enable physicians to quickly
access clinical information online. Epocrates, for instance, makes guidelines, reference
lists, tables, drug and disease information, dosing calculators, and other clinical
resources readily available online. Epocrates has over 75 mobile applications for
reference and education, suggesting information fragmentation that is overloading
providers with many disconnected tools.
EHR technologies were conceived to help doctors manage this information overload,
acting as an electronic warehouse system for patient data. The adoption of EHR
technologies in the United States, driven by the HITECH Act, provides an electronic
storage system for patient data. Several vendors are now certified EHR providers
including AthenaHealth, eClinicalWorks, and CareCloud. Adoption, which is in process,
intends to expand EHR functionality from data capture to cross system transmission
and decision support tools. The three meaningful use stages outline the vision for
growth (Figure 38).
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Stage 1:
Meaningful use criteria
focus on:
Electronically capturing health
information in a standardized
format
Using that information to track
key clinical conditions
Communicating that
information for care
coordination processes
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2014
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across multiple settings
More patient-controlled data
Stage 3
2016
Improved
outcomes
Stage 3:
Meaningful use criteria
focus on:
Improving quality, safety, and
efficiency, leading to
improved health outcomes
Decision support for national
high-priority conditions
Patient access to self-
management tools
Access to comprehensive
patient data through patient-
centered HIE
Improving population health
Figure 38: Stages of Meaningful Use
(HealthlT.gov, 2012)
This multistage progression represents a substantial departure from the current
functionality of medical records. Data collected today is used once, and is not forward
accessible. Availability of this data for reuse and learning is the subject of nearly eight
IOM reports is at the heart of clinical support systems that are discussed in the next
section. The challenge is developing the science that will enable reuse of data for the
purpose of learning.
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5.3 Clinical Decision Support (C)
The availability of electronic patient data, in combination with clinical libraries and
knowledge warehouses, lays the foundation for clinical decision support (CDS) tools.
These tools are intended to assist providers in diagnosis and evaluation of patient data
at the point of care. There are already several types of CDS systems with varied
functionality and aspirations, including IndiGO, Clinical Looking Glass, UpToDate, and
VisualDx.
Inputs into the CDS system are patient symptoms, physician observations, and test
results, as well as medical journals, books, and online reference tools. Today's systems
use decision support rules to analyze patient history, looking for patterns and gaps in
care. The outputs may go from recommended tests, outlining possible diagnoses,
interventions, and treatment plans. The expectation is physician productivity will
increase as EHR platforms become more widely available and become integrated with
CDS systems.
Archimedes IndiGO (Individualized Guidelines and Outcomes) is developed by Kaiser
Permanente and is the commercialization of the Archimedes Model. IndiGO is a CDS
system that takes patient-specific data into account to create individualized guidelines,
calculate the statistical risk of common adverse events, and suggest interventions.
Another CDS example is the Clinical Looking Glass (CLG), developed at the Montefiore
Medical Center in New York. CLG provides decision support and allows the medical
center to conduct retrospective studies.
As shown in the interaction diagram (Figure 36), CDS tools can be used throughout the
three interaction phases and their value to providers relies on the quality of the input
data and accuracy of the algorithms. Today we are limited to front end statistics.
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5.4 Claim Management Analytics (D)
The extraordinary volume of claims data (nearly 400 terabytes for Medicare alone)
presents an obvious source of analytics that has already been adopted in other
industries. Several analytics companies are now providing services to payors and
providers with the aspiration to increase quality of care through reducing waste, cost,
and fraud. Companies like Predilytics and Verisk Health assert that claim databases can
be used to predict outcomes, identify miscoding, and enhance revenue. These
companies use machine learning on claims databases, demographic, and financial
information to develop predictive models of disease risks, patient disenrollment, and
readmission to hospital.
Claim analytics are used to extract information about interactions and not based on
care metrics. The incentives are for cost management, and are not focused on
improving outcomes. Additionally, as explained in section 2.4, the information in the
claim is limited to codes and administrative data which does not have the medical
value needed to make care decisions.
5.5 Genetic Testing (E)
We reviewed patient access to genetic testing in section 5.1.2. More laboratories are
offering specialized genetic testing services directly to providers. Genetic tests are
used in the clinical care setting to inform diagnosis, prognosis, risk prediction,
prevention, and treatment selection for many disorders and diseases. More than 1,700
genetic tests are now available, but only a few are regulated by the FDA ("Genomics -
HealthyPeople.gov," 2012). Certified testing labs and molecular diagnostic companies
send test kits to providers, clinicians collect patient's blood sample or oral swab, and
send it back to the lab for analysis. Several companies also provide educational
services to the patient, once results are known. The availability of this individualized
data is envisioned to yield a more objective diagnosis process.
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There are several genetic tests available
for cancer diagnosis and treatment.
Myriad and Foundation Medicine provide
tests that are intended to inform cancer
risk and specify particular mutations or
abnormalities in existing tumors. This
genomic analysis, in some cases, helps to
select care regiments. Myriad's product
offerings are listed to the right.
Breast Cancer/Ovarian Cancer
BRACAnaivsis
Colon Cancer
COLARIS'
COLA nf
Melanoma
MELAR RS
Pancreatic Cancer
IM I
Prostate Cancer
5-FU Dose Optimization
On
Managing Chemotoxicity
I I Te t i n
PTEN Testing
Figure 39: Myriad Cancer Products Offerings
Companion diagnostic research is becoming a focus during drug development, with
over eighty partnerships between pharmaceutical and diagnostic companies
(Westenberg, 2012). Companion diagnostics can be used to stratify patients that are
most likely to benefit from a drug. The intent is to prevent unnecessary costs due to
ineffective medication usage and to help narrow the treatment landscape. Only a few
products have been approved to market alongside therapeutics.
The data retrieved from genetic testing intends to help providers make better-
informed clinical decisions, given that the tests are highly accurate. There are
numerous concerns in adoption including false positives, testing overuse, genetic
discrimination, and excessive distress that comes with positive disease prediction. The
science is still advancing and we currently are only witnessing the very beginning of one
avenue of personalized medicine.
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5.6 Open Innovation Initiatives (F)
As shown in the interaction diagram and discussed in chapter 4, manufacturers
produce exorbitant amounts of product data while developing new medical products.
The breadth of data and span of development process introduces an opportunity for
collaboration across companies and academia. We observe several innovation trends
in the various phases of the commercialization process: discovery, clinical trials, and
approval process.
Eli Lilly's Open Innovation Drug Discovery (OIDD) Platform and Sage Bionetworks are
examples of collaboration during drug discovery. Both platforms are designed to
expand the drug discovery and disease research networks through engaging the
broader scientific community. Lilly's platform enables researches to submit their
molecular compounds for screening using Lilly's internal assays via a complimentary
web-based application (Eli Lilly, 2011). Using Lilly's established evaluations tools,
researchers can quickly learn about the potential of their compound and can further
collaborate with Lilly on advancing development. The goal of open innovation during
discovery is the use of collective efforts to reduce the time and cost of the phase.
Traditionally, only a subset of product data is made public, although there is increasing
belief that the medical community could not only benefit from this data, but could add
value to the development process. TLS is one such example. Transparency Life
Sciences (TLS) has created an open platform to design and execute clinical trials
using crowd sourcing. Involving all stakeholders, TLS welcomes input from
medical experts, researchers, physicians, patients, families, and regulators. The
web-based platform enables collaboration of all participants in protocol design
and data analysis in real time. Figure 40 shows the steps involved in clinical
trials and TLS's leverage point at each step.
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Figure 40: Transparency Life Sciences Process Leverage Points
(TLS, 2012)
Regulators are also proponents of open research data. The European Medicines Agency
(EMA) published a memorandum in 2012 calling for the need of open clinical trial data,
a response from a series of questionable trial data from Roche (Tamiflu) and
GlaxoSmithKline (Avandia, Paxil). (Appendix D) The EMA proposes that clinical trial
data should not be considered commercial, confidential information and patients who
enroll in a trial do so with an assumption of contributing to medical knowledge (Eichler,
Abadie, Breckenridge, Leufkens, & Rasi, 2012). Also in 2012, the British Medical Journal
established the Open Data Campaign, which aims to achieve appropriate and necessary
independent scrutiny of data from clinical trials (BMJ). GlaxoSmithKline announced
support for BMJ's Open Data Campaign and is beginning the process to release
individual-level data.
5.7 Product Licensing (G)
Several initiatives are now underway to enhance drug commercialization, led by the
regulatory bodies of the United States and Europe. A current focus is on new drug
development concepts to accelerate approval, which takes many names including:
* Staggered approval (EMA)
* Progressive reduction of uncertainty (FDA)
* Progressive authorization (Health Canada)
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* Test bed for adaptive regulation (HSA Singapore)
* Managed entry (payors, HTAi)
Traditional drug licensing approaches, as described in section 2.6, are based on binary
decisions, at the moment of licensing an experimental therapy is transformed into a
safe treatment option (Eichler, Oye, et al., 2012). Regulatory decisions are based on
incomplete data, but delaying approval even further would deny patient access to a
potentially beneficial, life-saving drug. In a recent paper published in Nature by a
consortium of researchers and stakeholders, led by MIT NEWDIGS, adaptive licensing is
explained as a prospectively planned, adaptive approach to the regulation of new
drugs, integrated with iterative phases of data gathering followed by regulatory
evaluation and license adaption (Eichler, Oye, et al., 2012). Adaptive licensing, and
other accelerated approval models, aspires to yield timely access to drugs through
continuous monitoring once implemented.
5.8 Distribution Management and Analytics (H)
Prescription dispensing and expenditure in the United States is on an upward trend,
reaching four billion scripts in 2011 (Lindsley, 2012). Distributors such as PBMs, as
discussed in chapter 2, share the same incentives as payors to track medication
alignment, assess compliance, and monitor safety risks. The volume of pharmacy
claims give PBMs insight to prescribing patterns and many are leveraging analytics to
provide added-value services for cost reduction. For instance, Express Scripts and CVS
Caremark have recently begun pharmacogenomic programs, with the intention to
intercept prescriptions and assess whether an appropriate genetic test is available to
further inform treatment selection and prevent ineffective medication usage. Also
dubbed, Genetics Benefit Management, these programs attempt to harness the
benefits of genetic testing by educating both prescribers and patients of existing tests,
and then providing the follow-up testing service. Generation Health, recently acquired
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by CVS Caremark, analyzes prescription claims to identify patients that may benefit
from genetic testing. This aims to ensure that patients receive the right therapy and
right drug dosage, through optimizing the usage of genetic tests.
Drug licensing changes and other accelerated approval mechanisms, will require more
monitoring and control of product distribution. One solution is the Medbox, a
medication dispensing system that manages inventory and compliance. Medication is
stored in a temperature-controlled unit and dispensing is controlled by biometric
identification (fingerprint sample). The Medbox confirms that the user is a registered
patient that has authorization to access the medication. Every transaction is
documented and patient data is used to drive accurate dispensing.
5.9 Localized Feedback (I)
The final stage in the interaction diagram is the monitoring loop, where the
intervention effect is assessed for benefits and risks. This is often the most difficult
piece of data to obtain, as after intervention, the patient may not continue to engage
with the health system. However, several new technologies are being developed to
improve data collection post-intervention. Proteus Digital Health has created an
ingestible sensor that is manufactured in a pill to detect ingestion time and physiologic
data. High quality feedback related to the effects of the drug is recorded after the pill
is swallowed. An external patch captures and transmits data to a mobile device.
CardioMEMS is another technological breakthrough that measures blood pressure and
heart rate in patients with chronic heart disease through a miniature sensor implanted
into the pulmonary artery. The sensor wirelessly sends pressure readings to an
external device. The data retrieved off of these devices is sent to the clinical care team,
enhancing the available data for intervention assessment.
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A slew of other remote monitoring devices that track vital signs, as previously
discussed, can also be prescribed to patients to enhance the data pool. The Patient
Centered Medical Home (PCMH) initiative provides an incentive for new companies in
the monitoring device market. Several devices now have the capability to transfer real-
time patient data, collected remotely, to EHR systems.
Another method of feedback is the reporting of adverse events to manufacturers and
regulators. The FDA has previously relied only on the passive Adverse Event Reporting
System (FAERS) for voluntary patient and provider reports of product safety issues.
FAERS has proven to be insufficient with the low volume of reports and poor data
quality. Mini-Sentinel is a FDA pilot project that is creating an active surveillance
system, which uses claims and medical records to seek safety issues of marketed
products. The system is driven by a safety hypothesis and queries data from dozens of
partner sources for assessment. Although significant effort has been put into
developing the system, its use is limited to research validation and is not designed to
be used at the point of care.
5.10 Summary of Trends
The interaction diagram in Figure 36 serves as a comprehensive map to explore the
current trends across the health system. Improvement initiatives are paired with the
data inefficiencies described in chapter 4. Each initiative focuses on a segment of the
system and aims to optimize the data for its own benefit. For instance, the basis of
payor analytics is to reduce costs and it is arguable whether patient outcomes are a
secondary or even tertiary priority. Another conundrum is the use of
pharmacogenomics to identify patient subsets that will likely respond to a therapeutic.
For a pharmaceutical or biotechnology company, this limits their market and greatly
affects revenue potential. Even though companion diagnostics promise less waste and
more efficiency, the limited number of patients is detrimental to the manufacturers'
bottom line.
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CHAPTER 6: CONCEPT OF A LEARNING HEALTH SYSTEM
In chapter 4 we introduced a flow diagram that explains data emerging from the
patient interaction with the care system. And in chapter 5, we traversed the diagram
to identify how data is used and identified emerging trends in data collection and use
that point to opportunities for local enhancements to the system. Understanding how
to translate these observations into system wide learning is the focus of this chapter.
In this chapter we propose a system architecture concept that favors learning. We
start with a topological transformation of the interaction diagram (Figure 35) that
moves us away from the sequential representation of patient interactions, in favor of
groupings of form and function. The system architecture that results - shown in object-
process notation in Figure 42 - has all of the elements needed to achieve optimal data
usage that supports learning. The rest of the chapter connects this new architecture
with the current system, the various local optimizations it is undergoing, and various
interpretations of learning in the health system - such as the ones proposed in the IOM
learning healthcare series of reports (Institute of Medicine, 2012).
6.1 Functional Architecture
In Figure 41, we reorganize the interaction diagram, focusing on form and function.
Although they are visually very different, Figure 35 and Figure 41 are topologically
identical; that is, they capture the same information about patient interaction but
emphasize different aspects of the system. Figure 34 emphasizes the temporal
sequence of events while Figure 41 emphasizes the nature and function of data and
processes associated with that interaction. We identify five distinct clusters of
activities: collected patient data, aggregated data, diagnosis/treatment selection,
treatment approval, and product approval.
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PRODUCT APPROVAL
Figure 41: Functional Architecture of the Interaction Diagram
Figure 41 shows the clustering of activities as either data or process. Data comes in
two flavors, either associated with an individual patient interaction with the system or
aggregated and possibly anonymized. Process categories sort activities by the
decisions and functions associated with treatment, its approval/distribution, and the
development/approval of new products. The next two sections further review these
activities.
6.1.1 Data Categories in Figure 41
The collected patient data category consists of all forms of data that are originally
sourced from the patient, namely vital measurements, clinical test data, and medical
claims. Since the patient is the common thread across this data category, we can
envision a single data repository for each patient. Such a repository is technically
feasible with advances in electronic medical records, personal health records, and real-
time monitoring devices (sections 2.3, 5.1). A repository for patient data that is fully
managed would allow patients to record their health record and state of health
continuously - for health management or piecemeal sharing with care providers and
other stakeholders.
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The aggregated data category includes prior knowledge, experience, accrued
population data, publications, policies, and product information. These are all the
sources of information that result from aggregating data, be it cohort data, scientific or
regulatory data, etc. These are the kinds of data that are currently being used to drive
clinical decision support systems (CDSS), like IBM Watson and Archimedes IndiGO
(section 5.3). Compiling this breadth of information into a single system could become
the basis for a health information/knowledge exchange that supports learning.
The combination of these data categories results in knowledge creation driven by
patient data. The data from the patient repository can be combined with the
aggregated data to make care decisions on individual patients, inform public health, or
used for research. This new data connection makes the system wide learning cycle
explicit and, to the best of our knowledge, has yet to be implemented in the current
system.
6.1.2 Process Categories in Figure 41
From the standpoint of data, there are three markedly different processes:
diagnosis/treatment selection, treatment approval and distribution, and product
approval. Diagnosis/treatment selection consists of various provider interactions with
the patient to collect data for diagnosis. Each interaction between the patient and
provider is reviewed for reimbursement by the payor - treatment approval process.
The product approval process is embodied in the manufacturer and regulator loop and
consists of the activities involved in manufacturing and licensing new medical products
for distribution to the patient.
These processes have naturally different workflows and objectives; however, they all
rely on the same set of input data from the two data categories described in section
6.1.1.
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6.2 System Concept Emerging From Figure 41
All engineering systems have an object-process nature (Crawley, 2011). The division of
the system into data and process categories represented in Figure 42 can be cast in
terms of Crawley's architectural framework of systems. We do so by identifying
collected patient data as operands and aggregated data as instruments. In Crawley's
systems framework, instruments support the transformation of operands by processes.
This interpretation, shown in Figure 42, confirms our expectation about the health
system, namely that the three processes we identified act differently on data. It also
helps identify why the current system struggles to incorporate learning. For learning to
occur, we need a process that routinely reverses flow: the current operands need to
become instruments and the current instruments need to become operands.
operands processes instruments
Clinical
Individual Knowledg
Patient Data Warehouse
Patient Data songd
Selected Patients' Gonanc
Figure 42: Synthesized System in Object-Process Notation
The simplified view of the functional architecture in object-process notation in Figure
42 allows us to use a different framework to validate our representation of the system.
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6.2.1 A Learning Health System
Figure 43 shows a graphical representation of a new system that contains the topology
of Figure 41, but in which we synthesized categories. We combine some of the arrows
and, in doing so identify new functions that were not obvious in any of the previous
diagrams that emphasized temporal sequence.
Figure 43: Learning Health System Concept
The current system and its three interaction phases - examination, diagnosis, and
intervention - are still represented in this diagram, but they are represented now as
different iterations around the single loop. For instance, during patient encounters, the
provider uses newly collected data, information from past visits, and aggregated data
for diagnosis and treatment selection. The next set of processes is triggered to approve
the intervention selected by the provider. Once the intervention request is approved,
patient data continues to feed back into both data repositories.
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This system diagram allows us to identify elements that are implicit in the previous
system that map to opportunities for learning that we identified in chapter 4.
Collectively they represent the architecture vision of a health system designed for value
assessment and knowledge management. The green arrows represent learning and are
not standard in today's system. These arrows indicate the flow of data to and from the
collected patient data repository and the aggregated data repository. The addition of
the green arrows indicates that the system has two functions: improve individual
patient care and contribute to global knowledge. The accrual of collected patient data
into the aggregated data repository indicates that every patient contributes to overall
learning. As well, every process performed and decision made also contributes to
learning. The provider assessment/decision support function supports opportunities
for direct learning from these two data repositories.
The payor assessment/distributor loop uses better information for value assessment
and supports the notion of value for learning. The product manufactured/approval
loop moves from outside of the system to within and by doing so, supports the models
for accelerated licensing. These two subsystems act as a checks and balances system
to define value as a combination of learning and outcomes. Therefore, as a design
choice, we group these together as if they were a single subsystem.
The activities within the product manufactured/approval loop are concealed in the
patient interaction diagram, but are analogous to the activities in the care system. The
difference is that the manufacturer assumes the payor role by following the regulatory
process. Integrating this loop into the care system, as proposed in Figure 43, enables
continuous monitoring post intervention.
Collectively, the data repositories and emerging functions show value to the health
system from lessons learned from broader data exposure. The system is designed to
learn from each patient interaction, supplying better data to each subsystem function.
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6.3 System Problem Statement, Revisited
In chapter 1 we defined the system problem statement based on our assessment of the
stakeholder's needs and system goals. The future system vision deviates significantly
from how we generally think about the health system; the future state for the health
system we propose introduces learning as an integral component. This new vision
emerges from our stakeholder interviews, analysis of the system inefficiencies, and
concept vision of a learning health system. We express this shift by revising the system
problem statement:
To maintain the health of individuals,
By learning at every interaction, activity, process, and function,
Using all the information acquired through data analysis, practice of
medicine, and science.
The result of this new model is a system that benefits both the individual patient and at
the same time supports knowledge generation and learning. Value is derived from
every interaction and intervention, and lessons are drawn out of each process to better
maintain the health of the next individual. Central to the future vision is the
requirement for a custodial health "bank" for every individual and a health knowledge
and information exchange. The evolution of individual information transforms into
system wide learning.
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CHAPTER 7: CONCLUSION
We envision a new architecture for the system of health where each patient interaction
with the health system presents an opportunity to contribute to knowledge. We show
that the system can be architected as a single loop, where data is generated,
interpreted, and reused for analysis and decision-making. The loop considers value
delivered to the patient directly and through learning. This data driven architecture for
the health system is compatible with the current system but also points to a path to
enable system wide learning. This architecture, introduced in chapter 6, is the main
contribution of this thesis.
We took a principled stand that learning in health requires a deliberate approach to
handling, collecting, analyzing, and interpreting data. That is, a learning health system
is necessarily an information based system. Our analysis reveals that the current
system does not effectively transfer data across interfaces; we showed that much in
chapter 5 with our overview of data driven solutions that are emerging locally to
compensate for partial access to information. Nevertheless, our data overview in
chapter 2 reveals there are abundant opportunities to incorporate better data and
better data practices into the health system. Chapter 3 tells us, though, that the
traditional stakeholder view of the health system does not help us understand how to
incorporate those into the existing system. The stakeholder agnostic view of health
data we took in chapters 4 and 5 helped us uncover hidden functionality in the system,
such as distributor review functions and the two markedly different categories of data
that support our vision for a data driven system designed for value and learning. The
discovery of said functions, the landscape overview of data, and the methodology we
used to remove stakeholder and temporal biases from the traditional view of the
system are also contributions of this thesis.
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7.1 Findings Supporting New Vision
The following is a summary of the findings, spread over chapters 3-5, that support the
vision laid out in chapter 6.
e The entry of data from outside the clinical environment into the care system is
narrow and there is no standard method for the system to broadly accept these
measurements. This data, in the form of physiological measurements for
instance, presumes to offer a more comprehensive view of patient status
enabling monitoring between encounters.
* Adoption of EHRs helps advance towards an improved management of patient
records, but does not resolve uncertainties about the desired evolution of care
delivery in a learning health system. Understanding how to compare different
patient records and how to enhance interconnectivity across patient and
provider systems will facilitate learning, but remains undefined.
* Automated generation of claims from EHRs may reduce translation errors but
does not address systematic errors induced by the limitations of the disease
code system, and the propagation of these errors to coverage decisions and
outcomes.
- Data released by manufacturers has limited value because it is based on
population statistics of a pre-defined patient group and is aggregated for public
use, and it is hard to relate to the needs of a specific patient. The development
process may benefit from contributing data for system wide learning.
e There is no standard mechanism to give feedback on approved products.
However, the same processes are shared between the care system and the
approval system, although they have different objectives. There is an
opportunity to design monitoring and learning mechanisms in the care delivery
process that feed from the lessons learned in the approval process.
e The drug approval process, by design, releases products that provide a benefit
to only a small percentage of patients who receive them (Aspinall &
Hamermesh, 2007). Patient specific data as input into the development process
may improve the rates of efficacy for medical products, by, for instance,
updating the attributes of the population likely to benefit from said medical
product.
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7.2 Future Work
We are at the cusp of a health system transformation. Our analysis suggests that the
current stakeholder perspective is not yet fully compatible with a shift towards a health
system that is personalized, predictive, preventive, and participatory, our conclusion
matches the observations (Hood & Friend, 2011) make about the need to realign
stakeholders to reduce waste and improve system inefficiency. The architecture of the
system proposed in chapter 6 is a good starting point to engage in new research on the
redefinition of the scope of stakeholders by the value associated with health data.
The patient's role needs to shift from a passive receiver of care to an engaged
consumer. Objective data sourced from the patient is highly valuable, but needs to be
complemented with systems capable of managing this voluminous amount of data to
extract meaning. Patient specific information must also be comparable to enable
broader usage across the process subsystems defined in chapter 6, such as in drug
development - as a basis for personalized medicine. An avenue for future research is
the development of new "big data" tools that enable the manageability and
comparability of this data. The conclusions in chapter 6 may be used as an architecture
to understand the areas in which such tools are needed, for instance, to support the
transition from individual to collective data and back to aid decision-making, or to
ensure that the delivery system derives lessons to be incorporated into the proposed
health information exchange (aggregated data repository in Figure 43).
Our analysis highlights the weak connections between the product manufacturer
subsystem with the care delivery system, distinct segments driving health that
communicate only through a narrow interface - e.g. labels, medication guides, and
adverse event self-reporting. New drug approval models are being proposed, such as
adaptive licensing, that blur the boundaries between pre and post-approval. While the
transition to a progressive means of licensing has received a lot of attention, an
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uncertainty remains about how to link monitoring practices pre and post approval. The
learning system we proposed suggests one approach to think about this problem.
The evolution of a health system from one that traces diseases to one that manages
health implies a shift from an accidental accrual of health data to a deliberate design
data streams. This data will be used to generate evidence to inform decisions and
ultimately extract knowledge for continuous learning. This thesis lays the foundation
and further research is proposed to continue development of the architecture of a data
driven health system.
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APPENDIX B: STAKEHOLDERS' NEEDS
PATIENT
Good health, high quality of life
Access to and affordable products, services, and care
Education on health, wellness, and treatment to make informed decisions about
prevention and care
Tools to manage health and disease
Education, knowledge, training on existing/new medical products, treatments, and tools
Access to health facilities, equipment, and medical products (drugs, devices)
Awareness by patient, provider, and payor networks
Efficient, thorough, timely examination of patients to collect dataPROVIDER Database for patient administration and clinical information
Communicate and transfer information to patients, provider networks, and payors
Tools and applications to inform decision making and monitor patients to assess
outcomes
Payment from payors and patients
Record of services performed by prviders and record of medical products distributed to
patients
Knowledge of new/existing medical products, to evaluate payment coveragePAYOR Payment from patients, patient employer, government
Database to receive patient and provider information and to analyze and process claims
Reduce long term costs by maintaining health of members minimizing services and
products needed
Knowledge of disease biology, molecular chemistry, medical science
Materials to manufacture drugs
Ability to test safety and effectiveness of drugs
Sample human population to test drug
MANUFACTURER Feedback on product outcome
Obtain approval for license
Reduced time to market
Reduced development costs
Revenue from customers (payors, patients)
Funding for development, manufacturing costs
Protect public safety
REGULATOR Support/resources from government
Complete information to evaluate drug/device products
Monitoring product post-approval
Access and storage of products
Dispensing system to track incoming prescriptions, outgoing products, and transactionsDISTRIBUTOR for reimbursement
Product cost breakdown between payor and patient
Patient information and prescription history to assess distribution safety
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Access and engagement with network of others with similar conditions for support
Ability to explain and communicate symptoms, feelings, state, etc.
Privacy and security of Dersonal data
IAPPENDIX C: PARTITIONED DSM, SECTION 3.2
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APPENDIX D: TAMIFLU CASE STUDY
Tamiflu (oseltamivir) is Roche's influenza antiviral and during its 1999 approval
by the FDA, the effectiveness of the drug was questionable and believed to be
no better than aspirin or acetaminophen (Doshi, Jefferson, & Del Mar, 2012).
However, there was tremendous pressure to commercialize Tamiflu, as
governments around the world, following the guidance of the WHO, stockpiled
the drug. With its assumed benefit, Tamiflu sales surged during the 2005 and
2009 influenza pandemics, raking in $4.6 billion for Roche. Since then, there
has been a growing controversy related to the effectiveness of Tamiflu and
Roche's claims of reduced complications, hospitalizations, and prevention of
transmissions have been challenged.
In 2009, the Cochrane Collaboration embarked on an independent analysis of
the effectiveness of Tamiflu and compared published data with unpublished trial
records. The Cochrane team, led by Peter Doshi and Tom Jefferson, claimed
that the datasets made available by Roche provided incomplete and
inconsistent evidence and there were several discrepancies between the
published and unpublished data. As well, the published documents failed to
acknowledge the serious adverse events (neurologic events such as
hallucinations, convulsions, and encephalitis) which were identified during the
clinical trials and have since been widely reported. The controversy over
Tamiflu's clinical data continues, and Roche has still yet to provide the additional
trial data that has been requested by the Cochrane team.
The Tamiflu example suggests that there is currently no mechanism that
transcends the valuable data that is created during clinical trials beyond the
development purview. This creates a fragile data connection between the
manufacturer and other stakeholders, realizing a substantial data loss.
Validation of this observation has recently emerged. Inspired by the Cochrane
reviews of Tamiflu, the European Medicines Agency (EMA) has responded to
the notion of open clinical trial data. The EMA agrees with the Cochrane claim
that clinical trial data should not be considered commercial confidential
information and patients who enroll in a trial do so with an assumption of
contributing to medical knowledge (Eichler, Abadie, et al., 2012). However,
independent review of trial data may risk quality, conflict of interest, and misuse.
The EMA further proposes that availability of trial data may be realistic if
personal data protection can be assured, quality standards of meta-analyses
adopted, and rules for raw data sharing implemented.
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